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Nano- and Micro- Technology Approaches to Enhance Drug Delivery 
Elizabeth Levy 
 
ABSTRACT 
 Small molecules and protein therapeutics are constantly being developed due to their high 
potency and biological function, but there are many barriers that reduce the therapeutic efficacy 
of these compounds such as a short half-life leading to high clearance, and biological 
degradation. As a result, to overcome these challenges higher doses have to be administered with 
increased frequency to reach a therapeutically relevant concentration. To address these issues 
nano- and micro- technology has been utilized to increase drug absorption. This dissertation 
presents various approaches to drug delivery based on the disease target, application, and 
therapeutic compound.  We showed that hydrogel microdevices reversibly inhibit intestinal 
efflux transporters P-glycoprotein and Breast Cancer Resistance Protein, resulting in an increase 
in drug absorption. We demonstrated in a Caco-2 model that this decrease in efflux transporter 
function was due to a decreased amount of transporter present on the cell surface in the presence 
of microdevices. Also, presented are two polymer nanoparticle-based systems designed for 
different disease targets. First, for cancer immunotherapy we designed a nanoparticle loaded with 
an adjuvant cocktail with a tumor specific peptide to promote antigen presenting cell activation 
and downstream tumor specific T cell activation. Therapeutically, these drug-loaded 
nanoparticles were able to decrease tumor volume in a subcutaneous melanoma model and 
melanoma foci in a metastasis model. Second, in atherosclerosis where arteries were damaged, 
we showed that tissue factor peptide targeted nanoparticles loaded with an anti-inflammatory 
agent were able to target desired damaged arteries where tissue factor is typically exposed. The 
	 vii	
strategies presented here expand the application of nano- and micro- technology for design and 
implementation in a variety of different diseases and targets. We have shown increased drug 
absorption and efficacy not only by increased drug half-life but by targeted therapeutics to 
desired regions resulting in increased local concentrations.  
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CHAPTER 1:  Reversible Inhibition of efflux transporters by hydrogel microdevices* 
Abstract 
Oral drug delivery is a preferred administration route due to its low cost, high patient 
compliance and fewer adverse events compared to intravenous administration. However, many 
pharmaceuticals suffer from poor solubility and low oral bioavailability. One major factor that 
contributes to low bioavailability are efflux transporters which prevent drug absorption through 
intestinal epithelial cells. P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) 
are two important efflux transporters in the intestine functioning to prevent toxic materials from 
entering systemic circulation. However, due to its broad substrate specificity, P-gp limits the 
absorption of many therapeutics, including chemotherapeutics and antibacterial agents. Methods 
to inhibit P-gp with competitive inhibitors have not been clinically successful. Here, we show 
that micron scale devices (microdevices) made from a commonly used biomaterial, polyethylene 
glycol (PEG), inhibit P-gp through a biosimilar mucus in Caco-2 cells and that transporter 
function is restored when the microdevices are removed. Microdevices were shown to inhibit P-
gp mediated transport of calcein AM, doxorubicin, and rhodamine 123 (R123) and BCRP 
mediated transport of BODIPY-FL-prazosin. When in contact with Caco-2 cells, microdevices 
decrease the cell surface amount of P-gp without affecting the passive transport. Moreover, there 
was an increase in mucosal to serosal transport of R123 with microdevices in an ex-vivo mouse 
model and increased absorption in vivo. This biomaterial-based approach to inhibit efflux 
transporters can be applied to a range of drug delivery systems and allows for a 
nonpharmacologic method to increase intestinal drug absorption while limiting toxic effects. 
 	*	Modified from the publication:  Levy, E. et.al (2018) Reversible Inhibition of efflux 
transporters by hydrogel microdevices. Eur J Pharm and Biopharm 123:502-514.	
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Introduction  
Oral drug dosing is the preferred route of delivery due to its convenience, safety, and low 
cost.1–4 However, many drugs suffer from poor solubility and low oral bioavailability which can 
limit their therapeutic effectiveness. Factors that contribute to low bioavailability are the low pH 
of the stomach, intestinal metabolizing enzymes leading to drug degradation, and the 
hydrophobic mucosal layer and efflux transporters preventing intestinal drug absorption. 1,5 
Efflux transporters of the multigene ATP binding cassette (ABC) transporter family such as P-
glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-
associated protein 2 (MRP2) are expressed on the apical membrane of intestinal epithelial cells.6 
These transporters efflux absorbed compounds from the intestinal cells back into the 
gastrointestinal (GI) lumen, thus preventing them from reaching the systemic circulation.6 Efflux 
transporters function to protect the small intestine from harmful toxins and xenobiotics by 
limiting their absorption.7,8 However, most efflux transporters have broad substrate specificity 
which translates into poor oral bioavailability for a significant number of therapeutics.6,8–10  
Many strategies have been employed to inhibit the function of efflux transporters to 
increase drug absorption.7,11,12 P-gp is the most widely studied efflux transporter since it limits 
the bioavailability of numerous substrates, including chemotherapeutics, immunosuppressants 
and antimicrobial agents.7 The main approaches studied for P-gp inhibition include competitive 
inhibitors that directly block the site of drug binding and noncompetitive inhibitors that either 
block the hydrolysis of adenosine triphosphate (ATP) necessary for P-gp function or 
allosterically interact to reduce P-gp activity.7,13–15 However, decades of research aimed at 
targeting P-gp through the use of chemical inhibitors provide limited evidence for clinical 
applicability.16,17 The lack of success using P-gp inhibitors to improve bioavailability underlies 
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the ongoing search for safer and more effective methods to address this critical limitation in oral 
absorption.15  
Micro- and nanotechnology-based drug delivery systems have been used as effective 
tools to increase drug absorption and enhance bioavailability.4,18 Previously, we have shown that 
nanostructured thin films increase drug permeation through the intestinal epithelium.19 We have 
also shown that microdevices increase residence time in the intestine and increase permeation, 
thus increasing drug bioavailability.20 Additionally, hydrogels are widely used in drug delivery 
because of their biocompatibility, ease of tunability, and their ability to increase bioavailability, 
thus allowing for improved absorption in target regions.21–25 In particular, PEG hydrogels are 
commonly used for oral drug delivery as PEG is non-immunogenic and biocompatible.26–28 PEG 
based nanoparticles have been investigated for their ability to modulate permeability in vitro. 23 
Additionally, PEG in a non-crosslinked form was shown to limit P-gp activity with evidence 
indicating the changes are due to alterations in the microenvironment of P-gp.29 Altering the 
molecular weight of the non-crosslinked PEG has been shown to alter the degree of P-gp 
inhibition; however, there is not a clear correlation between PEG molecular weight and P-gp 
inhibition.30,31 Hydrogel and polymer based microparticles, however, have a decreased residence 
time in the intestine which is limited by peristaltic flow that dislodges the hydrogel material.32 
The overall goal of this study is to investigate the effects of hydrogel microdevices to 
improve drug absorption through gastrointestinal epithelial cells.  Since PEG-based hydrogels 
are commonly used in various controlled release systems, gaining a basic understanding of their 
effects on efflux transporters is essential for the development of improved oral delivery systems. 
Biocompatible PEG-based drug delivery microdevices were developed and optimized for 
adherence to the intestinal epithelial wall and reversible inhibition of efflux transport. The data 
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presented below supports this approach for maximizing drug absorption, increasing oral 
bioavailability, and limiting toxicity of orally administered substrates of P-gp and BCRP.   	
 
Materials & Methods 
Fabrication of microdevices 
Microdevices with a diameter of 200 µm and a thickness of 20 µm were fabricated as 
previously described.33 Briefly, a solution consisting of 80% w/v 750 number average molecular 
weight (Mn) polyethylene glycol dimethacrylate (PEGDMA) (Sigma-Aldrich), 10% w/v 
IRCAGURE (2-Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone) (Sigma-Aldrich) in 
dimethyl sulfoxide (DMSO), and 10% w/v deionized water was added to the surface of a piranha 
cleaned 3” silicon wafer (Addison Engineering Inc) at a thickness of 20 µm. The wafer is 
brought into contact with a photomask with 200 µm exposed features and irradiated with a 365 
nm UV light source using a Karl Suss Mask Aligner for 1 minute to crosslink the PEGDMA. The 
solution viscosity is important for appropriate spreading on the wafer. The wafer is then removed 
and the polymer that is not crosslinked is washed away in water. The microdevices are then 
removed from the wafer into ethanol. Prior to studies, microdevices are washed with sterile 2% 
Bovine Serum Albumin (BSA) solution (Sigma-Aldrich).  
Cell culture 
Human colon adenocarcinoma cell line (Caco-2) purchased from ATCC was maintained 
in 2D cell culture as previously described.19 Caco-2 cells between passage 5 and 13 were used 
for all experiments. Mycoplasma test was performed on the cell line and found to be negative. 
Cell culture experiments are performed in two formats, on transwells and 96 well plates. Cells 
are seeded at 75*103 cells/cm2 and cultured for 21 days for transwell experiments. For 
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experiments performed in a 96 well plate, cells are seeded at 27*103 cells/cm2 and cultured for 
14 days. Cell	growth	conditions	were	optimized	so	that	P-gp expression levels between the 
transwells and 96 well plates were similar. 
Immunohistochemistry 
Caco-2 cells cultured on transwells for 21 days were fixed as described previously.19 
DAPI (1:500) and Alexa 488 Phalloidin (1:200) (Life Technologies 1726566) were used to stain 
the cells. After staining, transwells were cut out and mounted on a slide with slowfade gold 
antifade reagent with DAPI (Invitrogen). Cells were imaged with a Tokagawa CSU22 spinning 
disk confocal microscope. 
Transwell culture 
Caco-2 cells were seeded at 75*103 cells/cm2 on high density polycarbonate Transwell 
inserts (24-well, 0.4 uM pore size) (Corning) as described previously.19 Cells were cultured for 
21 days before use in experiments.  
Viability studies 
Caco-2 cells were seeded at a density of 27*103 cells/cm2 on a 96 well plate. After 14 
days of culture the cells were washed, and a PrestoBlue assay was performed. Briefly, 
microdevices were added to the wells and incubated for 3 hours. The microdevices were 
removed and PrestoBlue cell viability Reagent (Invitrogen) added to the wells. After a 10-minute 
incubation at 37°C the absorbance was read at 570 nm. Wells without microdevices were used as 
controls.  
Dead cells were measured by propidium iodine (PI) staining. Cells were grown in a 
transwell for 21 days, after which microdevices were added for 3 hours. The cells were lifted by 
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cell dissociation buffer and stained with 2 mg/mL PI for 5 minutes. The cells were washed 3X 
and placed in 2% BSA solution to run on flow cytometry (BD FACS Calibur).  
An ATP assay kit (Abcam) was used to determine total levels of cellular ATP in Caco-2 
cells grown on a transwell model for 21 days. Cells were treated in the absence or presence of 
microdevices for 3 hours. After 3 hours, phenol red free Minimum Essential Medium (MEM) 
(Gibco) is removed and detergent is added to lyse cells and stabilize ATP. Substrate solution 
provided by the kit is added and luminescence is measured after 15 minutes. 
Transport studies 
The calcein AM assay was performed in a 96 well plate. Caco-2 cells were grown on 96 
well plates for 2 weeks. After the cells were washed with phenol red free MEM, 3 µM calcein 
AM in the presence and absence of microdevices or CSA, positive control inhibitor of P-gp, was 
added to the wells and incubated at 37°C. After 1 or 3 hours the cells were lysed to determine the 
intracellular calcein concentration. Cellular levels of calcein were normalized to protein 
determined by a micro bicinchoninic acid (BCA) protein assay kit (ThermoFisher). To test active 
vs passive transport, the calcein AM assay was run at 4°C. 
Prior to transport experiments, cells were washed with phenol red free MEM. The following 
substrates were added to the basolateral chamber to measure P-gp or BCRP transport: 5 µM 
rhodamine 123 (R123) (Invitrogen), 10 µg/mL doxorubicin (LC Laboratories) or 5 µM 
BODIPY-FL-prazosin (Invitrogen). The microdevices, 15 µM CSA (Sigma-Aldrich), or 50 µM 
Ko143 (Sigma-Aldrich) were added to the apical chamber and incubated at 37°C. CSA and Ko 
143 are small molecule positive control inhibitors for P-gp and BCRP, respectively. The apical 
chamber was sampled over time and the fluorescence was measured using excitation 
(nm)/emission (nm) 495/560 (R123), 490/590 (doxorubicin), or 485/530 (prazosin). To account 
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for passively absorbed drug in the microdevices, the microdevices were removed after the 
experiment and placed in an eppendorf tube. The microdevices are centrifuged at 500 g for 4 
minutes and the supernatant is removed, sampled, and the fluorescence is measured. Fresh buffer 
is added to wash the microdevices. This process is repeated until there is no detectable 
fluorescence in the supernatant. The amount of drug absorbed into the microdevices was 
accounted for in calculating the amount of drug transported. Transport function recovery was 
studied after microdevice removal. The control, positive control, and microdevice wells were 
washed and phenol red free MEM was added to the apical chamber. The fluorescence in the 
apical chamber was sampled and measured over time. The apparent permeability coefficient was 
calculated according to the equation:  
!"## = %&'&( ) ∗ ( 1-./) 
where Papp is the apparent permeability (cm/s), dQ/dt (µg/s) is rate of drug transport, A is surface 
area of the transwell, and C0 (µg/mL) is the initial drug concentration. Transwells without 
microdevices were used as controls. Transepithelial electrical resistance (TEER) is measured at 
each time point. Apical to basal transport is studied by adding the drug substrate at the 
concentrations indicated above to the apical chamber with the microdevices or positive control 
inhibitors. The basal chamber is then sampled and analyzed. 
Biosimilar mucus transport study 
Biosimilar mucus consisting of 5% (w/v) mucin, 0.11% (w/v) linoleic acid, 0.36% (w/v) 
cholesterol, 0.18% (w/v) phosphatidylcholine, 0.163% (w/v) polysorbate 80, and 3.1% (w/v) 
BSA was prepared based on previously described methods.34 Biosimilar mucus at 250 µL/cm2, 
which is approximately 2 mm in thickness, was placed on the cultured Caco-2 cells in transwells. 
The mucus was incubated for 1 hour prior to the addition of microdevices, phenol red free MEM 
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(control), or CSA in the apical chamber and 5 µM R123 in the basolateral chamber. Transport 
assays were performed as described above. After the experiment was complete, the mucus layer 
was removed and the microdevices were visualized on the Caco-2 cells by microscopy. 
Passive permeability 
The passive transport of 4kDa FITC Dextran (Sigma-Aldrich) across the Caco-2 cell 
monolayer was performed as previously shown.35 Briefly, Caco-2 cells well grown on transwells 
for 21 days. FITC Dextran (2 mM, 4kDa) was added to the apical chamber with and without 
microdevices. The basal chamber was sampled, and the fluorescence was measured over time 
(Ex 485 nm/Em 530 nm). All experiments were done in triplicate at 37°C.   
Flow cytometry of cell surface P-gp 
The cell surface P-gp was labeled with fluorescent anti-P-gp monoclonal antibody (BD, 
Clone 17F9) and analyzed by flow cytometry. Briefly, Caco-2 cells grown on transwells for 21 
days were washed with phenol red free MEM. Microdevices were added to the apical chamber 
for 3 hours at 37°C. After 3 hours, the cells were removed from the transwell membrane with 
cell dissociation buffer. The cells were washed 3X and then incubated with Alexa Fluor 488-
conjugated mouse anti-P-gp monoclonal antibody at 4°C for 30 min. The cells were then washed 
3X with 2% BSA and analyzed by flow cytometry. Two transwells were combined for each 
sample to increase the cell number for flow cytometry. Transwells without microdevices were 
used as controls.  
mRNA expression of efflux transporters 
Microdevices were added to transwells cultured with Caco-2 cells for 21 days. After 3 
hours, RNA was collected from the transwell using RNeasy Mini kit (Qiagen). cDNA was 
generated from RNA with iScript cDNA Synthesis Kit (Bio-Rad). qPCR reactions were 
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performed with SYBR Green PCR Master Mix (Applied Biosystems). L19 is used as a reference 
control. Samples are compared to transwells without microdevices as a treatment control.  
Table 1.1: Gene and Primer Sequence for qPCR 
 
Ex-vivo mouse model 
Three BALB/c mice were sacrificed at 18-20 weeks of age. Jejenum of the intestine was 
isolated and solid waste was removed. The jejenum was sectioned into 4 cm long pieces. One 
end of the intestine was closed with a suture and 5 µM R123 was pipetted into the intestine 
section containing microdevices, CSA, or a control without treatment on the mucosal side. The 
other end of the intestine was tied off before the start of the experiment. The intestinal sacs were 
incubated in a 24 well plate in media at 37°C. The solution on the serosal side was removed, 
replaced with fresh media, and the fluorescence was measured at excitation 495 nm /emission 
560 nm over time. After the final sample was taken, the intestine was removed and measured to 
determine the surface area.  
Mouse studies 
 All mouse experiments were approved by the institutional animal care and use committee 
(IACUC) at Carnegie Mellon University (Pittsburgh, PA, USA) under protocol number 
PROTO201600017, and were performed in accordance with all institutional, local, and federal 
regulations. C57BL/6 mice were either purchased from Charles River Laboratories (Wilmington, 
MA, USA) or obtained from an institutionally managed breeding colony. Prior to experiments, 
mice were housed in cages of no more than five animals, with controlled temperature (25°C), 12 
Gene  Primer Sequence 
MDR1 F 5’-GCC AAA GCC AAA ATA TCA GC 3’ 
R 5’-TTC CAA TGT GTT CGG CAT 3’ 
ABCG2 F 5’-TGC AAC ATG TAC TGG CGA AGA 3’ 
R 5’-TCT TCC ACA AGC CCC AGG 3’ 
L19 F 5’-TCGCCTCTAGTGTCCTCCG 3’ 
R 5’- GCGGGCCAAGGTGTTTTTC 3’ 
	 10	
hour light-dark cycles, and free access to food and water. Mice utilized in this study were male 
and 8 – 16 weeks old (16 – 26 grams). The free-to-use PS power calculator (Vanderbilt) was 
used to determine the minimal sample size for which statistical power was greater than or equal 
to 0.8. (n = 5 – 7). Mice were fasted for 12 hours the night before an experiment to limit the 
variability caused by food matter and feces in the GI tract. Oral gavages and phosphate buffered 
saline (PBS) rehydration were administered at a volume of 10 ml solution per kg of mouse body 
weight (10 μL/g). 
Oral delivery of rhodamine 123 
Fasted mice were orally gavaged with one of three treatment solutions: 40,000 
microdevices/mL solution (400,000 microdevices/kg total dose), 0.5 mg/mL (5 mg/kg) 
cyclosporine A (CSA) as a positive control, or phosphate buffer saline (PBS) as a negative 
control. Every treatment also contained 9.6 mg/mL (96 mg/kg) BSA to stabilize the solution. 
Thirty minutes (controls) or two hours (microdevices) later, submandibular blood was collected 
from each mouse to provide baseline fluorescent values, and each mouse received a gavage of 
0.4 mg/mL (4 mg/kg) R123. Submandibular blood was collected at 10, 20, 30, and 60 minutes 
following the R123 gavage, and mice received subcutaneous PBS rehydration after the 30 and 60 
minute blood draws. At 240 minutes, the mice were euthanized and final blood collected via 
cardiac puncture.  
All samples were centrifuged to isolate the serum, which was removed and examined for 
R123 concentration by reading for fluorescence on a Tecan Spark® automated plate reader 
(495/560 nm). Application of a R123 calibration curve, in the presence of mouse serum, yielded 
the reported concentrations of the model drug in each sample. 
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Statistics 
Statistical analysis was performed by a two-way ANOVA with a Tukey’s multiple 
comparison correction to determine significance between groups. Analysis between two groups 
was performed by a two-tailed t-test. Plots show mean ± standard deviation (SD) where * 
represents p<0.05, ** represents p<0.01, and *** represents p<0.001. 
 
Results and Discussion  
Microdevice characterization 
Uniform 200 µm biocompatible PEG microdevices were fabricated by photolithography. 
Briefly, PEGDMA, deionized water, and initiator (IRGACURE) were mixed and a thin layer was 
added to a silicon wafer. The mixture was irradiated through a 200 µm mask to form crosslinked 
microdevices (Figure 1.1A). Microdevices were visualized with bright field microscopy (20 µm 
x 200 µm) (Figure 1.1B). Microdevices did not alter cell viability or metabolic activity as 
indicated by staining of dead cells with propidium iodide (PI) and with a Presto Blue assay 
which measured the reducing power of living cells (Figure 1.2A). The microdevices also did not 
affect ATP amounts, indicating viable cells (Figure 1.2A).  
In Figure 1.2B, microdevices were visualized on top of cells with confocal microscopy. 
Microdevices were added for 3 hours on a Caco-2 monolayer grown on transwells for 21 days. 
Immunostaining shows an intact confluent monolayer of Caco-2 cells expressing actin 
underneath the devices (Figure 1.2B).   
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Figure 1.1: Fabrication of PEGDMA microdevices using photolithography. A) Schematic 
representation of the microdevice formation using ultraviolet (UV) light irradiation. B) 
Brightfield (5X) image of microdevices. Scale bar 100 µm. C) Transwell model system with 
Caco-2 cells grown on transwell insert membrane for 21 days and microdevices added to the 
apical surface of the intestinal monolayer. 
 
Figure 1.2: Characterization of microdevices in Caco-2 cells. A) Biocompatibility studies of 
the microdevices on Caco-2 cells with a propidium iodide (dead) stain, PrestoBlue assay, and 
ATP assay (two-tailed t-test, Mean ± SD; n=3). B) Fluorescence confocal images (10X) of 
microdevice (Scale Bar =100 µm) and of microdevices incubated for 3 hours on Caco-2 cells 
grown on transwells for 3 weeks (60X) showing the microdevices in brightfield (BF), DAPI 
nucleus (blue) stain, and phalloidin actin (green) (representative image of n=3 wells). Scale Bar 
=10 µm. 
 
	 13	
Microdevice inhibition of efflux transporters 
Efflux transporters decrease oral bioavailability by pumping drugs that get absorbed into 
the intestinal cells back out into the GI lumen, preventing drugs from entering the systemic 
circulation.6 First, the effects of the microdevices on P-gp function were tested. P-gp is a critical 
efflux transporter in the intestine with a broad substrate specificity and a determinant of oral 
bioavailability of many drug substrates from chemotherapeutics to immunosuppressants.7 
Microdevices were shown to inhibit the transport of multiple model P-gp substrates, including 
calcein AM, doxorubicin, and R123. Calcein AM, a non-fluorescent P-gp substrate that freely 
diffuses into the cell is rapidly cleaved intracellularly by esterases to form fluorescent calcein, 
which is not a P-gp substrate. Inhibition of P-gp results in an accumulation of calcein AM inside 
the cell and a corresponding increase in hydrolysis to calcein and higher fluorescence. 
Microdevices (3000 microdevices/cm2) increased the intracellular concentration of calcein to a 
similar degree as a positive control small molecule inhibitor, CSA, indicating P-gp inhibition 
(Figure 1.3A). P-gp inhibition by microdevices was also studied in a transwell system where the 
Caco-2 cells were cultured on transwell membrane inserts for 21 days (Figure 1.1C). The TEER 
at the time of study was greater than 350 W•cm2, indicating tight epithelial junctions. 
Doxorubicin is a chemotherapeutic which freely diffuses into the cell when added to the basal 
chamber and then gets transported by P-gp into the apical chamber. Microdevices at 3000 
microdevices/cm2 were placed on the Caco-2 cells in a transwell decreased efflux of doxorubicin 
into the apical chamber, consistent with P-gp inhibition (Figure 1.3B). The apparent permeability 
(Papp) is defined by the drug transport rate, initial drug concentration, and the surface area of the 
transwell insert. Papp decreased in Caco-2 cells with the microdevices or when treated with CSA 
(Table 1.2). The P-gp substrate R123 was also tested in Caco-2 transwells. R123 was added to 
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the basolateral chamber and transported into the cell where it is subsequently effluxed into the 
apical chamber by P-gp. We tested whether the level of inhibition was dependent on the dose of 
microdevices with the addition of 3000 microdevices/cm2 or 900 microdevices/cm2 to the apical 
chamber. While we have seen significant decrease of R123 with both doses compared to control, 
the 3000 microdevices/cm2 showed a higher degree of inhibition more similar to CSA (Figure 
1.3C). The Papp decreased with the microdevices and CSA (Table 1.2). To test whether the 
microdevices permanently alter transporter function, we performed a transporter recovery assay. 
R123 transport by P-gp recovered following removal of the microdevices to levels comparable to 
cells without microdevices, indicating reversible inhibition of P-gp (Figure 1.3D). Reversibility 
of transporter function is important as these efflux transporters function to prevent toxic material 
from entering systemic circulation. Therefore, permanently decreasing transporter function could 
result in toxic adverse effects.7,8 
Since there is significant overlap between P-gp and BCRP substrates, the effects of the 
microdevices on BCRP function were also tested using the BCRP substrate BODIPY-FL-
prazosin (prazosin). Prazosin freely diffuses into the cell and is effluxed out on the apical 
membrane by BCRP. As a positive control we used a potent BCRP specific inhibitor, Ko143. 
Microdevices (3000 microdevices/cm2) decreased basal to apical transport (Figure 1.4) and 
decreased the prazosin Papp to a similar degree as Ko143 (Table 1.2). As shown previously, 
efflux transporters often work in concert with each other, with one efflux transporter increasing 
function in response to loss of function of another efflux transporter, thus limiting drug 
absorption.36  Inhibition of both P-gp and BCRP by the hydrogel microdevices is predicted to 
enhance the increase in intestinal absorption. 
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Figure 1.3: Inhibition of P-gp transport by microdevices in Caco-2 cells.  A) Caco-2 cells 
were grown on 96 well plates for 14 days before measurement of intracellular calcein AM 
transport. Both the canonical P-gp inhibitor CSA and microdevices (3000 microdevices/cm2) 
inhibited P-gp as indicated by increased intracellular calcein concentrations (two-way ANOVA, 
Mean ± SD; ***p<0.0001; n=3). B) Caco-2 cells were grown on transwell membranes for 21 
days prior to measurement of doxorubicin flux from the basolateral to apical compartments. The 
values shown are the cumulative amounts of doxorubicin transported into the apical chamber at 
each time (two-way ANOVA, Mean ± SD; ***p<0.0001; n=3). Doxorubicin flux was decreased 
by microdevices (3000 microdevices/cm2) and CSA. Shown is one representative experiment of 
3 independent experiments. C) R123 flux from the basal to apical chamber was measured in the 
presence and absence of microdevices and CSA. The values shown are the cumulative amounts 
of R123 measured in the apical chamber (two-way ANOVA, Mean ± SD; ***p<0.0001 w.r.t. 
untreated control; n=3). Microdevices and CSA both inhibited R123 flux and more inhibition of 
P-gp was seen with 3000 devices/cm2 than 900 devices/cm2. The two microdevice doses are 
significantly different at T=3 (*p<0.05) and T=4 (***p<0.0001). Shown is one representative 
experiment of 4 independent experiments. D) Recovery experiment with R123 where devices 
are removed, and transport into the apical chamber is measured over time. No difference is seen 
between the conditions once the devices are removed (two-way ANOVA, Mean ± SD; n=3). 
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Figure 1.4: Microdevices inhibit BCRP transport in Caco-2 cells. Caco-2 cells were grown 
on transwell membranes for 21 days prior to measurement of prazosin transport. The values 
shown are the cumulative amounts of prazosin measured in the apical chamber (two-way 
ANOVA, Mean ± SD; ***p<0.0001 w.r.t. untreated control; n=3). Microdevices inhibit 
prazosin transport to a similar degree as CSA. Shown is one representative experiment of 3 
independent experiments. 
 The	P-gp	and	BCRP	substrates	used	in	these	studies	diffuse	into	the	cells	when	placed	on	the	basolateral	side	of	Caco-2	cells.	P-gp	then	actively	transports	R123	and	doxorubicin	while	BCRP	transports	prazosin	out	of	the	cell	into	the	apical	compartment.	Measurement	from	the	basal	to	apical	chamber	allows	for	direct	measurement	of	the	function	of	the	efflux	transporters.	Others	have	shown	that	there	is	minimal	to	no	difference	in	the	absence	and	presence	of	an	inhibitor	when	these	substrates	are	added	to	the	apical	side	and	detected	on	the	basolateral	side.37–41	We	see	similar	results	with	established	P-gp	and	BCRP	inhibitors,	likely	due	to	an	insufficient	change	in	the	concentration	gradient	in	the	presence	of	inhibitor	to	detect	concentration	differences	in	the	basolateral	chamber.					
Microdevices function through biosimilar mucus 
The intestine has multiple barriers to prevent drug absorption, including the intestinal 
mucus. Although the mucus acts as a protective barrier to prevent bacterial microbes and toxic 
material from reaching the epithelial cells, it can also prevent drugs and drug delivery 
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formulations from interacting with these cells. A biosimilar mucus was used to test the effects of 
the microdevices in a transwell system.34 The mucus was added to the apical chamber and 
allowed to incubate for 1 hour. Afterwards, the P-gp substrate R123 was added to the basal 
chamber and 3000 microdevices/cm2 were added on top of the mucus layer. Similar to the 
experiments without mucus, microdevices inhibited P-gp as indicated by a decrease in R123 flux 
into the apical chamber; however, this inhibition of P-gp was delayed due to the need for the 
devices to permeate through the mucus for access to the transporter (Figure 1.5). While the effect 
of the microdevices on P-gp occurred within 2 hours without the mucus layer, inhibition was not 
detected until 4 hours after adding the microdevices with the mucus. Interestingly, the inhibitory 
effect of the microdevices was greater than that of CSA in the presence of mucus.  This may be 
due to the small molecule being entrapped in the mucus and unable to interact with P-gp on the 
cell membrane. The microdevices were visible on the Caco-2 monolayer upon removal of the 
mucus layer. We hypothesis due to the weight and size of the microdevices that they are able to 
displace the mucus layer allowing them to travel through the mucus to interact with the 
membrane transporters on the cell surface. Compared to control, Papp decreases with 
microdevices to a similar extent as with CSA (Table 1.2). As the mucosal layer is a barrier to cell 
accessibility and drug absorption, the ability of the microdevices to penetrate this mucosal layer 
is critical for interaction with the intestinal cells to inhibit efflux transport. 
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Figure 1.5: Microdevices inhibit P-gp transport through biosimilar mucus. Caco-2 cells 
were grown on transwell membranes for 21 days prior to measurement of R123 flux from the 
basal to apical chamber in the presence and absence of microdevices (3000 microdevices/cm2) 
and CSA. The values shown are the cumulative amounts of R123 measured in the apical 
chamber at specific times (two-way ANOVA, Mean ± SD; ***p<0.0001 w.r.t. untreated control; 
n=3). Microdevices and CSA both inhibited R123 flux under conditions of a biosimilar mucus 
layer. Shown is one representative experiment of 3 independent experiments. 
 
Microdevices affect P-gp function by decreasing cell surface expression 
The possibility that the microdevices inhibit drug permeation by altering tight junctions 
was evaluated by measuring permeation of 4kDa FITC dextran. In the Caco-2 transwell system, 
the Papp for the 4kDa FITC dextran solution and the percentage that permeates the cell monolayer 
was unchanged with the addition of 3000 microdevices/cm2 (4.7% permeation after 4 hours in 
the absence and presence of microdevices), indicating that the microdevices are not affecting 
paracellular drug transport (Figure 1.6A). To further test if the transport mechanism is active or 
passive, transport studies were performed at 4°C and 37°C. Inhibition of calcein AM transport 
with the microdevices was only apparent when the cells were kept at 37°C, indicating active 
transport is required for microdevice function (Figure 1.6B). In addition, we do not observe any 
changes in TEER with the microdevices present indicating the microdevices are not affecting 
paracellular drug permeation. 
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Figure 1.6: Microdevices do not affect passive permeability of Caco-2 cells. A) Caco-2 cells 
were grown on transwells for 21 days prior to measurement of apical to basal flux of 4 kDa FITC 
Dextran transport. The values shown are means ±SD of 3 biological replications. There was no 
effect of the microdevices on FITC dextran flux indicating no effect on tight junctions. B) Caco-
2 cells were grown on 96 well plates for 14 days prior to measurement of intracellular calcein 
concentrations at 4°C. The values shown are means ±SD of 3 biological replications. There was 
no effect of the microdevices on calcein accumulation at 4ºC. 
 
The effect of the microdevices on P-gp expression was also considered. To test whether 
the microdevices were affecting transporter expression levels on the mRNA level, qPCR was 
performed. P-gp and BCRP mRNA levels remain unaltered after 3 hours of treatment with the 
microdevices compared to control (Figure 1.7A).  Due to the short time scale of hours in the 
microdevice treatment, a change in mRNA levels is not necessarily expected. To further test if a 
direct change in cell surface P-gp protein amounts were altered in the presence of the 
microdevices we performed flow cytometry. Briefly, Caco-2 cells grown on transwells were 
exposed to microdevices for 3 hours, stained with a P-gp antibody that recognizes an external 
epitope, and analyzed by flow cytometry. Exposure to the microdevices caused a decrease in 
levels of P-gp on the cell membrane when compared to untreated cells (Figure 1.7B). We 
propose that the decrease in cell surface P-gp is due to the interactions with the microdevices, 
which then leads to decreased P-gp function. The structure of P-gp in the transmembrane domain 
has been shown to be tightly integrated with cholesterol and phospholipids, and this interaction is 
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critical for transporter dynamics.42 Whether the microdevices affect P-gp function by disrupting 
these interactions requires investigation. Consistent with previous work, altering the cell surface 
interactions of the transporter can indeed affect transporter function.43 Additionally, it is 
plausible that the microdevices sterically hinder the conformational changes required for P-gp to 
release a substrate from the binding site in the transmembrane region to the apical chamber, 
resulting in P-gp inhibition. Such steric hinderance could also lead to internalization of the 
transporter as supported by the decrease membrane expression after exposure to microdevices 
(Figure 1.7B).  
 
Figure 1.7: Microdevices decrease cell surface P-gp levels in Caco-2 cells. Caco-2 cells were 
grown on transwells for 21 days and A) mRNA levels corresponding to P-gp (ABCB1) and 
BCRP (ABCG2) in the absence and presence of microdevice exposure for 3 hours were 
measured by qPCR. B) Following the same treatment of Caco-2 cells with microdevices, cell 
surface P-gp levels were analyzed by flow cytometry. P-gp levels are expressed relative to levels 
in cells without microdevices (two-tailed t-test, Mean ± SD; ***p<0.0001; n=9). Surface P-gp 
protein levels were decreased in cells after addition of the microdevices.  
 
Ex vivo mouse model to measure R123 transport 
Ex vivo models allow for increased complexity of intestinal epithelium interactions over 
2D culture methods while allowing for higher throughput over in vivo studies.44 We isolated and 
sectioned the mouse jejunum into 4 cm regions to generate intestinal sacs. The intestinal sacs 
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were loaded with R123 in the absence or presence of 3000 microdevices/cm2 or CSA on the 
mucosal side. The intestine was closed on both sides and transport of R123 across the intestinal 
barrier of the epithelial cells was measured on the serosal side. We showed a significant increase 
in transport of R123 to the serosal side in the presence of microdevices compared to control 
(Figure 1.8). The Papp increases in the presence of microdevices compared to control. This 
suggests that the microdevices were able to inhibit P-gp in a physiological ex vivo model, 
increasing drug transport across the cell to the serosal side. This ex vivo model better represents 
an in vivo oral dose where the drug substrate is interacting with the epithelial cells on the 
mucosal side to increase drug absorption to the serosal side. 
Figure 1.8: Microdevices increase mucosal to serosal transport of R123 in an ex vivo mouse 
model. Jejunum was sectioned to form intestinal sacs where R123 transport was measured over 
time in the presence and absence of microdevices (3000 microdevices/cm2) or CSA. A) Fold 
change of R123 transport compared to control, without microdevices. (Two-way ANOVA, Mean 
± SD; *p<0.05 w.r.t. untreated control, n=6 Control, n=4 CSA, n=6 Microdevices) B) 
Calculated Papp of R123 transport with an increase in Papp from 0.2*10-6 cm/sec (control) to 
0.35*10-6 cm/sec with microdevices and 0.33*10-6 cm/sec with CSA. R123 transport from 
mucosal to serosal side was increased with microdevices. (Two-tailed t-test, Mean ± SD;* 
p<0.05 w.r.t. untreated control, n=6 Control, n=4 CSA, n=6 Microdevices) 
 
In vivo mouse model to measure R123 Transport 
In vivo mouse models represent a more physiological environment where mucus, 
microbiome, and peristalsis flow which are difficult to represent in vitro are intact. Microdevices 
(400,000 microdevices/kg total dose), or CSA were given by gavage to C57BL/6 mice after a 12-
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hour fasting period. Microdevices were preincubated for 2 hours while CSA was preincubated 
for 30 minutes, then R123 was given by oral gavage to the mice. Blood was collected over time 
through a submandibular vein. A significant increase in R123 Cmax was measured with CSA and 
microdevices compared to control (Figure 1.9). The Cmax and AUC0-60min increase is consistent 
with changes in the absorption phase of R123. Previous studies in rodents demonstrated rapid 
systemic hydrolysis of R123 to the corresponding acid, R110.45,46 Since the fluorescence assay 
used to detect R123 will also detect R110, it is difficult to interpret potential effects on the 
elimination phase of R123, although inhibition of P-gp in the liver or kidney is not expected 
since the microdevices are too large to be absorbed. This suggests that microdevices are able to 
inhibit P-gp in vivo, even with multiple barriers in the stomach and intestine, leading to increased 
R123 absorbed into systemic circulation.  
 
 
Figure 1.9: Microdevices increase systemic circulation of R123 in an in vivo mouse model. 
Oral gavage of microdevices (400,000 devices/kg), CSA, and R123 was performed on C57BL/6 
mice where R123 transport was measured over time. A) Systemic R123 amounts measured in 
serum over time B) Cmax and AUC0-60min values analyzed from the concentration-time curve 
(two-tailed t-test, Mean ± SD; Cmax p=0.012 Control vs Microdevices; n=8 Control, n=5 CSA, 
n=8 Microdevices) 
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Table 1.2. Papp values of P-gp and BCRP substrates 
Papp (cm/s) (10-6) Control Inhibitor Microdevices 
R123 8.03 ± 3.5 2.03 ± 0.71 5.51 ± 2.4 
Doxorubicin 1.90 ± 0.35 1.33 ± 0.46 1.74 ± 0.25 
Prazosin 10.18 ± 0.25 8.21 ± 0.90 7.36 ± 1.7 
R123 with mucus 9.25 ± 3.8 3.53 ± 3.5 4.21 ± 0.51 
Papp was calculated in 3-4 independent experiments and the mean ±SD are represented in the 
table.  
 
 
Conclusions 
The importance of gut efflux transporters in limiting drug absorption is well recognized. 
Attempts at inhibiting efflux transporters as a strategy to improve bioavailability have been 
limited by adverse events.15 Thus, there is a critical need for novel strategies to inhibit efflux 
transporters to improve oral drug absorption, particularly for drug substrates such as 
chemotherapeutics and immunosuppressants. Here, a materials-based approach was applied to 
study the effects of biocompatible crosslinked PEGDMA materials and their effects on efflux 
transporters. Due to the frequent use of PEG based materials in oral drug delivery, it is important 
to better understand the cellular-level effects of these materials as they interact with the intestinal 
epithelium. Here we demonstrated that PEGDMA microdevices inhibit P-gp and BCRP in a 
transwell Caco-2 model. The inhibition of P-gp was dose dependent with a greater number of 
microdevices resulting in increased P-gp inhibition. Dose dependence allows for control of the 
degree of inhibition based on drug or patient characteristics. In addition, the P-gp inhibition was 
completely reversible upon the removal of the microdevices. Importantly, the microdevices can 
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function as P-gp inhibitors through a biosimilar mucus in vitro and increase mucosal to serosal 
drug transport in an ex vivo mouse intestinal sac model.  Furthermore, in an in vivo mouse model, 
the microdevices increase Cmax and AUC0-60min of R123 compared to control, indicating the 
microdevices are acting as P-gp inhibitors in vivo. The decrease in P-gp function is likely due at 
least in part to a reduction in P-gp on the cell membrane in the presence of the microdevices.  
Since the microdevices only interact with the surface of the intestinal cell and do not 
enter systemic circulation, our approach presents a nonpharmacological method to inhibit P-gp 
with the goal to limit toxicity and adverse effects from current small molecule inhibitors. These 
findings open new possibilities for oral P-gp inhibition with the potential to locally and 
reversibly inhibit P-gp using microdevices. A more extensive characterization of the mechanism 
by which microdevices inhibit P-gp is required to fully understand their interaction with gut P-gp 
and to support novel therapeutic approaches to improve oral drug bioavailability. While a 
representative fluorescent P-gp substrate, R123, was used as a model substrate, this system can 
be translated to drugs that have limited oral bioavailability due to P-gp efflux.  Moreover, the 
knowledge gained in this study will be broadly useful in the design of hydrogel-based oral 
delivery systems, particularly with drugs that are efflux transporter substrates.    
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CHAPTER 2:  Innate Activating Nanoparticles Lead to Activation of Antigen Presenting 
Cells to Reduce Tumor Burden 
Abstract 
Cancer immunotherapy has been a growing field based on exciting clinical results that 
have improved patient outcome. Even with the ongoing trials further investigating the benefits of 
activating the immune system there still are limitations due to toxicity, nonspecificity, and high 
dose requirements for therapeutic efficacy. Here, we show that with a nanomaterials approach 
combined with an adjuvant cocktail including a TLR9 agonist, STING agonist, and RIG-I 
agonist along with a melanoma specific peptide, decreased the tumor presence in a subcutaneous 
and metastasis model. These innate activating nanoparticles (iaNPs) internalize and activate 
antigen presenting cells downstream leading to the promotion of melanoma sensitized T cells. 
This combination adjuvant cocktail and biomaterials-based approach to activate the innate 
immune response provides further insight to the benefits of stimulating multiple activation 
pathways to promote tumor regression.  
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Introduction 
Due to the failure of current highly invasive treatments for cancer with traditional 
chemotherapy and radiotherapy, there is an urgent need for new therapeutic developments to 
improve outcomes and patient compliance. Oncolytic viruses have been studied to effectively 
promote anti-tumor response and immunity.1,2 Strategies involving oncolytic therapy are 
promising and multiple clinical trials are ongoing.3–5 Oncolytic therapy involves multiple 
different pathways resulting in the lysis of tumor cells and release of antigens, cytokines and 
pathogen-associated molecular patterns (PAMPs) which all promote the activation of antigen-
presenting cells (APCs).1,6 Downstream these APCs lead to promotion of tumor antigen specific 
CD4 and CD8 T cells which promotes tumor regression and death.7–9 Activated CD8 T cells 
release cytokines, and cause granule exocytosis and Fas ligand-mediated apoptosis to exert 
antitumoral effects.10 Similar to CD8 T cells, CD4 T cells can mediate tumor death through 
direct interactions with tumor cells through release of cytokines and Fas mediated pathway.11 
Additionally, CD4 T cells can also indirectly kill tumor cells through helper functions, 
improving the efficacy of tumor reactive CD8 T cells.9,12,13 The PAMPs pathway involves a 
variety of different mechanisms that could lead to APC stimulation and downstream activation of 
the JAK-STAT pathway to trigger local interferon (IFN) release. For example, PAMPs can 
induce Toll-like-receptor (TLR) binding and activation, stimulator of interferon genes (STING), 
and retinoic acid inducible gene 1 (RIG-I).2,6,14 As a result, we wanted to develop a potent system 
based off the oncolytic virus to activate TLR9, STING, and RIG-I pathways in tumors (Figure 
2.1).  
  CpG-ODN 1826 has been studied as a TLR9 agonist to treat cardiac dysfunction and 
cancer.15–17 TLR9 recognizes unmethylated CpG dinucleotides which are found in viral and 
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bacterial DNA.18 In a cell’s resting state, TLR9 is found in the endoplasmic reticulum but in the 
presence of CpG ODN the TLR9 colocalizes with the CpG ODN in the endosomal compartment 
resulting in binding and pathway activation.19 Upon binding to CpG ODN, TLR9 stimulation 
leads to activation of the Th1 pathway which can directly lyse infected cells by natural killer 
(NK) and cytotoxic T lymphocyte (CTL) activation.16,20 TLR9 stimulation also activates 
plasmocytoid dendritic cells (pDCs) to secrete type I interferons and to increase activation of B 
cells and pDCs which leads to T cell activation and an immune response (Figure 2.1). Overall 
TLR9 pathway activation can lead to tumor cell death directly through production of factors such 
as IFNa or indirectly though NK activation. As a result, to modulate the innate and downstream 
adaptive immune system, we included the CpG-ODN1826 TLR9 agonist in our adjuvant 
cocktail.  
 To activate the STING pathway, we investigated the STING agonist 3’3 cGAMP. STING 
is a transmembrane protein that is found on many APCs such as macrophages and dendritic 
cells.21 Pathogens produce cytosolic cyclic di-nucleotides (CDNs) which are recognized by 
STING and lead to pathway activation. The binding of 3’3 cGAMP with STING leads to 
signaling events resulting in an increase in IFNb expression (Figure 2.1).22–24 Similar to the 
STING activation, RIG-I activation induces the secretion of proinflammatory cytokines such as 
type I interferon alpha and beta.25 RIG-I is a cytosolic protein that recognizes viral RNA evoking 
the innate immune response. 5’pppdsRNA is an agonist to RIG-I, and once bound to the RIG-I 
receptor, RIG-I undergoes an ATP dependent conformational change exposing the caspase 
recruitment domain (CARD).26 Upon exposure of CARD domain, this leads to downstream 
signaling and active production of type I interferons (Figure 2.1). Interferons have been shown to 
upregulate MHC I and MHC II promoting APC activation along with promoting apoptosis of 
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tumor cells through the JAK/STAT pathway.27–29 Although RIG-I receptor targets RNA while 
STING receptor targets DNA, there is cross-talk between these pathways which can lead to 
amplification of the innate immune system.30 
 In addition to the RIG-I, STING, and TLR9 agonists, we combine a TRP-2 or gp100 
peptide which is specific for melanoma cells. TRP-2 and gp100 proteins are overexpressed on 
the surface of melanoma cells.31 Stimulation of the innate immune system with proinflammatory 
cytokine production and DC activation leads to downstream activation of the adaptive immune 
system by generation of TRP-2 or gp100 specific CD4 and CD8 T cells to target and reduce 
melanoma tumor burden (Figure 2.1).32–34 Tumor specific antigen therapeutics have developed 
into a promising therapy especially as a combination therapy with multiple current clinical 
studies (clinicaltrials.gov NCT04024800, NCT02754362).35 Generation of these antigen specific 
T cells allows for targeting of the cytotoxic T cells to the tumor to induce tumor cell death.  
Even though these therapeutics have shown promise to mechanistically reduce tumor 
burden, a limiting factor to achieve optimal therapeutic effect and tumor burden is exposure. 
Small molecule and protein therapeutics are cleared rapidly from systemic circulation and lack 
sufficient uptake into cellular targets, resulting in limited therapeutic effects.36,37 As a result, the 
development of a nanoscale system to efficiently protect the therapeutics from degradation, 
increase the systemic half-life, and efficiently internalize into the target cells has improved 
cancer immunotherapy formulations.38 Various nano-based carrier formulations have shown 
promising efficacy to deliver proteins and small molecules including polymer nanoparticles, 
liposomes, and hydrogels. 39–43 
With the aim to develop a therapeutic to address the challenges discussed above, we 
construct an innate activating nanoparticle (iaNP) composed of a biodegradable polymer loaded 
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with a potent combination of a TLR9 agonist, RIG-I agonist, STING agonist, and a melanoma 
specific peptide (TRP-2 or gp100). With this adjuvant combination we hypothesize that the iaNP 
would activate the innate immune system to increase APC presentation and downstream lead to 
activation of tumor sensitized T cells to target and kill tumor cells. We investigated and 
characterized the response of APC in the presence of iaNP in vitro and in vivo and the tumor 
efficacy response in vivo in both a melanoma subQ and metastasis model.  
 
Figure 2.1: Anti-tumor pathways activated with iaNPs. iaNP were loaded with STING, RIG-
I, and TLR9 agonist along with cancer cell specific peptide, TRP-2. (1) TLR9 agonist activated 
B and pDCs leading to type I interferon production and activation of APCs. (2) RIG-I and 
STING agonist promote type I interferon production and activation of APCs. (3) Activated APCs 
present the TRP-2 peptide on the surface leading to sensitizing T cells to generate TRP-2 specific 
T cells. (4) TRP-2 specific T cells can then target cancer cells that express the TRP-2 protein on 
the surface leading to anti-tumor efficacy. (5) TLR 9 agonist also leads to anti-tumor efficacy 
through the Th1 pathway and activation of CTL and NK cells to directly kill cancer cells. 
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Materials & Methods 
Nanoparticle fabrication 
 Nanoparticles (NPs) composed of carboxylic acid terminated poly (lactic-co-glycolic acid 
(PLGA) (PolySciTech) were made by double emulsion probe sonication. 1200 mg of 75:25 
lactic:glycotic (L:G) PLGA was dissolved in ethyl acetate (Sigma) at 50 mg/mL. CpG ODN 
1826 (TLR9 agonist, 75 µg, Trilink), 5’ppp-dsRNA (RIG-I agonist, 15µg, Invivogen), 3’3-
cGAMP (STING agonist, 150µg, Invivogen), and a melanoma peptide (TRP-2 or gp100, 2mg, 
Sigma) were solubilized in aqueous Limulus amebocyte lysate (LAL) water. Polyvinyl alcohol 
(PVA, Sigma) at 3% (w/v) was added at a 1:2 ratio of polymer drug solution to PVA. The 
mixture was probe sonicated on ice at 7-8 W which is equal to 30 amplitude for 5 cycles of 5 
second on and 10 seconds off to form NPs. The NP solution was diluted 10-fold with 0.3% (w/v) 
PVA and slowly stirred for 2 hours to evaporate the ethyl acetate. The NPs were purified first to 
remove large aggregates by centrifuging at 500 rpm for 10 minutes. Then to remove small NPs 
and unencapsulated drug, the NP solution was centrifuged at 13,000 rpm for 10 minutes. The 
NPs were lyophilized and stored at -80C. Prior to in vitro and in vivo work, the NPs were 
resuspended in 1% PVA in Phosphate Buffer Saline (PBS).  
Total drug payload 
Drug Loading was determined by Size Exclusion Chromatography (SEC). Mobile Phase 
was 0.05M Potassium Phosphate Buffer with 0.25M Potassium Chloride, pH 6.8 which was run 
at a flow rate of 0.35 ml/min over 20 minutes. Adjuvant loading was determined over time until 
total payload was released out of the nanoparticles in PBS. Rention times for the adjuvants were 
6.5 minutes for CpG ODN 1826, 5.9 minutes for 5’ppp-dsRNA, 7.5 minutes for 3’3-cGAMP, 
11.9 minutes for the TRP-2 peptide. 
	 36	
Mice and cell culture 
The mouse studies were performed in compliance with the University of California, San 
Francisco Institutional Animal Care and Use Committee guidelines with the approved Protocol 
AN110246. Wild type C57BL/6 mice were 6-8 weeks purchased from The Jackson Laboratory. 
Cell culture was performed with complete media containing RPMI 1640 with 10% Calf Serum 
(heat inactivated, Sigma), 1% Penicillin Streptomycin (Sigma), 1 mM Sodium Pyruvate (Sigma), 
1% HEPES (Sigma), 1x non-essential amino acids (Sigma), 50 µM of 2-beta mercaptoethanol 
(Sigma). B16-F10 melanoma cells (ATCC) were cultured in a T-75 flask until 70% confluency 
prior to injection. For IV melanoma administration, the cells were removed from the flask, 
washed with ice-cold Hank’s Balanced Salt Solution (HBSS) (Thermo), and filtered prior to 
mouse tail vein injection of 2.5*106 cells/mouse.44 Cells were maintained in a humidified 
incubator at 37°C with 5% CO2. J774.1 macrophages (ATCC) confocal experiments were 
performed with nanoparticles with a fluorescent polymer Cyano-Polyphenylene vinylene (CN-
PPV) (Sigma) incorporated to track the nanoparticles. Macrophages were activated overnight 
with Lipopolysaccharide (LPS) (10 ng/mL, Sigma) and cultured with nanoparticles for 3 hours 
prior to washing and imaging.  
 In vitro nanoparticle uptake and activation experiments 
Spleen was harvested from mice. Spleen was extracted and mashed through a 70 µm 
filter with PBS. Splenocytes were centrifuged down at 1500 rpm for 5 minutes. The pellet was 
resuspended into RBC lysis (0.83% ammonium chloride in 0.01 M Tris buffer) for 5 minutes at 
37C. Cells were washed 2 x with complete media. 1*106 cells were placed in 96 wells.  
For nanoparticle uptake experiments, cells were cultured with NPs with a CN-PPV fluorescent 
polymer incorporated for tracking for 48 hours. Excess nanoparticles were washed 3x with 
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Phosphate Buffer Saline (PBS) (Sigma) with 4% fetal bovine serum (FBS) (Sigma). Cells were 
stained for flow cytometry. 
For APC activation experiments, cells were treated with iaNP, NP only, and control no 
treatment. After 48 hours the cells were stained with antibodies and run on flow cytometry.  
Subcutaneous in vivo melanoma model 
Female C57BL/6 mice aged 6-8 weeks from Jackson Laboratory were inoculated with 
1*105 B16F10 cells in PBS buffer. Mice were treated with saline, NP only, iaNP, free 
unencapsulated drug 3 days after tumor inoculation every 3 days for a total of 4 doses. 
Intratumoral treatment was injected in 4 separate spots in the tumor for a total of 100 µL. For 
intravenous treatment, 200 µL of treatment was injected tail-vein. A caliper was used twice a 
week for tumor measurements. 
Intravenous in vivo melanoma model 
B16F10 melanoma was added IV to C57BL/6 mice. After 4 days treatment was 
administered either PVA only, NP only, or iaNP IV to the melanoma treated mice. Treatment 
was administered 3 times every 3 days. 3 days after the last treatment, the mice were sacrificed 
and the spleen, lymph nodes, and lungs were harvested. The number of lung foci and weight was 
measured upon removal prior to digestion. The spleen and lymph nodes were passed through 100 
µm filter. RBC lysis was performed on splenocytes. Lung was finely minced and digested in 
media containing collagenase XI (2 mg/mL, Sigma Aldrich), DNAse (0.1 mg/mL, Sigma 
Aldrich), and hyaluronidase (0.5 mg/mL, Sigma Aldrich) at 200 rpm and 37°C for 45 minutes. 
The lung suspension was diluted 10-fold with media, vortexed to disturb the pellet and passed 
through a 100 µm filter. After forming single cell suspensions, the lymph node, splenocytes, and 
lung cells were plated in a 96 well plate.  
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Protein Transport Inhibitor (GolgiPlug, BD) at 1uL/mL was added to single cell 
suspensions. Cells were then stimulated with 10 µg/mL of TRP-2 in culture for 12 hours. The 
cells were stained for flow cytometry. 
In vivo dendritic cell activation was measured 5 days after 1 dose of iaNP, NP only, or 
control no treatment. The mice were sacrificed and single cell cultures of the spleen, lymph node, 
and lungs were generated as described above. The cells were then stained for flow cytometry.  
Flow cytometry analysis and panels 
For flow cytometry experiments single cells are plated in 96 wells plates at 1-2 *106.The 
plate in centrifuged down at 2,000 rpm for 2 minutes twice with PBS+2% FBS. The cells were 
resuspended in 50 µL of surface antibody mixture and incubated at 4°C for 30 minutes. After 30 
minutes, the surface antibody was washed 2x with PBS with 2% FBS. Cells were resuspended in 
50 µL of Fix/Perm (1:4) for 30 minutes. Wells were washed twice with Perm Buffer at 2000 rpm 
for 4 minutes. The cells were then incubated with intracellular antibody stain for 30 minutes at 
4C. Cells were washed 2x with PBS 2% FBS and resuspended and stored in PBS FBS at 4°C. 
Flow cytometry was performed on Fortessa X-20 and data analysis was performed with FlowJo  
For cell uptake experiments the surface antibody stain contains anti-CD3-FITC, anti-CD11c-
PECy7, anti-CD11b-BV650, anti-CD45-Alexa700, anti-CD64-BV786, anti-B220-APCCy7, anti-
CD19-PE, Ghost Violet 510 viability dye (Tonbo). Nanoparticles with the CN-PPV incorporated 
polymer were analyzed in the PerCP channel.  
For APC activation in vitro and in vivo, a dendritic cell and a macrophage panel were 
studied. Surface antibody stain for the DC panel were anti-CD3-PerCP, anti-CD11c-PE-Cy7, 
anti-CD11b-BV650, anti-CD45-Alexa700, anti-MHCII-e450, anti-Ly6C-BV605, anti-CD86-
APC, anti-B220-APC-Cy7, anti-CD207-PE, and Ghost Violet 510 viability dye (Tonbo). 
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Surface antibody stain for the macrophage panel were anti-B220-FITC, anti-CD19-FITC, anti-
CD3-FITC, anti-CD11c-PECy7, anti-CD11b-BV650, anti-CD45-Alexa700, anti-MHCII-e450, 
anti-CD64-BV786, anti-CD24-APC eFluor-780, and Ghost Violet 510 viability dye.  
Macrophage intracellular antibody stain mix contained anti-IL10-APC and anti-IL12-PE.  
TRP-2 stimulation surface antibody panel was anti-CD45.2-FITC, anti-CD8-BV605, anti-CD45-
Alexa700, anti-CD4-BV650, anti-CD3e-BV711, anti-FOXP3-e450, and Ghost Violet 510 
viability dye. The stimulation intracellular antibody stain contained anti-Ki67-PECy7, anti-IFNg-
PE, anti-TNFa-PerCP710, and anti CTLA4-APC.  
Statistics 
One-way ANOVA with a Dunnett multiple comparison was used to determine significant 
between each group in GraphPad Prism. All plots show mean ± standard deviation (SD) where * 
represents p<0.05, ** represents p<0.01, and *** represents p<0.001 
 
Results 
Nanoparticle characterization 
PLGA nanoparticles loaded with CpG ODN 1826 (TLR9 agonist), 5’ppp-dsRNA (RIG-I 
agonist), 3’3-cGAMP (STING agonist), and a melanoma peptide (TRP-2 or gp100) were 
generated by double emulsion (Figure 2.2). Briefly, the polymer in organic solution was probe 
sonicated with the cargo in an aqueous solution to form an aqueous core surrounded by polymer 
in organics. An aqueous solution with the surfactant PVA was added to create the double 
emulsion with an aqueous environment. The nanoparticles size was characterized by Scanning 
Electron Microscopy (SEM) (Figure 2.2) and Dynamic Light Scattering (DLS). The 
nanoparticles (NPs) were 258.1 ± 60 nm with a polydispersity index (pdi) of 0.02 in a hydrated 
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form by DLS. Loading of adjuvants in the NPs was determined by Size Exclusion 
Chromatography (SEC): 3.7 % of CpG ODN1826, 0.35% 5’ppp-dsRNA, 2.29% 3’3-cGAMP, 
and 30% melanoma peptide TRP-2. 
 
 
 
 
 				
Figure	2.2	iaNP	characterization.	SEM	Scale	Bar	500	nm.		
 
Systemic delivery of nanoparticle encapsulated innate agonists induces anti-tumor 
responses in syngeneic mice 
 Recent publications have shown the need to utilize drug delivery carrier systems to 
increase the residency time and potency of therapeutics while limiting systemic toxicity.37,44 We 
believe that the short half-life with unencapsulated agonists can be improved with nanoparticles 
to increase anti-tumor responses. As a result, we wanted to understand the effects of 
nanoparticles as a carrier system with intratumoral (IT) and intravenous (IV) administration. For 
these studies, the iaNP contains CpG, RIG-I agonist, STING agonist, and gp100. Melanoma cells 
were subcutaneously (subQ) injected into the mouse flank. After the tumors were palpable, the 
mice were treated with PBS vehicle, nanoparticles (NP) only, iaNP, unencapsulated drug combo 
and the tumor volume was monitored (Figure 2.3A). The tumor size aggressively grew with PBS 
vehicle when treated with IT injection (Figure 2.3B). There was a moderate decrease in tumor 
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volume with unencapsulated drug combo with IV administration. However, iaNP treatment IV 
significantly decreased the tumor volume indicating the presence of nanoparticles encapsulating 
the drug combo was critical to increase the efficacy of the therapeutic (Figure 2.3B). 
When comparing IT injections, aggressive tumors with large tumor volume were seen 
with the empty NP only and the PBS vehicle. The tumor volumes decreased with treatment 
where the unencapsulated drug combo performs moderately better than the iaNP when 
administered IT (Figure 2.3C).  
Figure 2.3: Systemic and intratumoral administered of iaNP reduces tumor volume in 
asubcutaneous melanoma model. (A) Timeline (days) for B16F10 melanoma cell subcutaneous 
inoculation, treatments, and sacrifice for tissue harvest. (B,C) Tumor volume of measured 
subcutaneous tumor over time (days). Each data point represents one animal. (B) Treatment with 
intratumorally administration of vehicle PBS, NP only, unencapsulated drug combo, and iaNP. 
(C) Treatment with intravenous administration of unencapsulated drug combo and iaNP and with 
intratumoral injection of vehicle PBS.  
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iaNP reduce tumor burden in lung metastasis model 
We hypothesize that systemic delivery of a therapeutic iaNP formulation may have 
efficacy in a metastatic tumor model. To study this effect, we modeled a metastatic tumor, where 
B16F10 cells were injected IV through the tail vein. Tumor inoculated mice were treated 4 days 
later with iaNPs delivered intravenously every 3 days for a total of 3 doses. (Figure 2.4A). The 
iaNPs contained CpG, RIG-I agonist, STING agonist, and TRP-2 for these studies. Therapeutic 
efficacy was assessed by harvesting lung tissue to quantify tumor foci. (Figure 2.4C). 
Remarkably, there was significant reduction in metastatic melanoma foci in the lungs with less 
than 40 foci observed in iaNP treated animals when compared to saline treated animals that had 
an average of 116 foci (Figure 2.4B). Modest decrease in tumor burden resulted with NP only 
treatment while iaNP treatment significantly decreased tumor burden (Figure 2.4B). As a result, 
the combination of nanoparticles with the drug combo led to an improvement in the metastatic 
melanoma presence in the lung tissue with 25% of the animals with less than 5 nodules. 
iaNP are internalized by antigen presenting cells  
iaNP were NPs loaded with innate agonists designed to activate DCs and promote antigen 
presentation. We studied cellular uptake of iaNP as well as downstream cellular activation. An in 
vitro macrophage cell line, J774, was cultured with fluorescently labeled NPs and imaged with 
confocal microscopy (Figure 2.5A). Increasing concentrations of nanoparticles resulted in 
increased nanoparticle positive cells analyzed by flow cytometry (Figure 2.5B). When further 
investigating the specific cell types that were nanoparticle positive, we saw a significant increase 
in nanoparticle uptake of 9.35% for classic dendritic cells (cDC), 20.43% for plasmacytoid 
dendritic cells (pDC) and 32.16% for macrophage with minimal (<0.5%) uptake from T and B 
cells (Figure 2.5C). From these results we showed selective uptake into these APCs. 
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Figure 2.4: Systemically administered iaNP reduces metastatic melanoma burden in lung 
tissue.  (A) Timeline (days) for B16F10 melanoma cell intravenous inoculation, treatments, and 
sacrifice for tissue harvest (B) Number of Lung Foci. Data is normalized to the control and 
presented as mean ± s.d N ³ 6. Each data point represents one animal. One-way ANOVA. ** 
denotes p<0.01 (C) Representative lung from WT mouse with melanoma foci with no treatment 
(control), nanoparticles only and iaNPs. 
   
Figure 2.5: Nanoparticle (NP) uptake by antigen presenting cells ex vivo. Confocal image of 
(A) J774 cells after 3 hour incubation with fluorescently labeled nanoparticles ex vivo. Scale bar 
5 µm. Nucleus dapi stain- purple, Actin Phalloidin stain- blue, and nanoparticles in yellow. (B) 
Concentration dependent nanoparticle uptake into splenocytes by flow cytometry. Data 
represents mean ± s.d., N=4. (C) Nanoparticle internalization by antigen presenting cells after 3 
hours of nanoparticle incubation determine through flow cytometry. Control wells have no 
nanoparticles present. Data represents mean ± s.d., N=4, Two-way ANOVA, *** denotes 
p<0.001. 
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Next we investigated the activation of these DCs following iaNP internalization. CD86 is 
a protein expressed on the surface of APCs that binds to the CD28 ligand on T cells.45 With iaNP 
treatment there was a significant increase in broad DC activation compared to control and no 
change with the NP only group (Figure 2.6A). To further understand the subset of the activated 
dendritic cells we focused on cDC and pDC. Both cDC1 and cDC2 activated cells increased with 
iaNP treatment while there was a larger about 2 fold increase in CDC2 compared to control 
(Figure 2.6B,C). Although generally the pDC population in splenocytes is low, the iaNP 
significantly increased the number of activated pDC compared to control while no change was 
present with the NP only group (Figure 2.6D). As B cells play a role in the adaptive immune 
system and when activated lead to antibody production, we further investigated the effects of 
iaNP on this cell population. NP only did not alter the population of activated B cells while iaNP 
significantly increased the number of these B cells (Figure 2.6E). When investigating the effects 
of iaNP on secretion of cytokines by macrophages, IL-10 amounts were unchanged, but there 
was a significant increase in IL-12 (Figure 2.6F,G). iaNP were selectively delivered to APCs and 
induce significant cellular activation as measured by CD86. 
We further studied an in vivo system where the iaNP, NP only and control were 
administered IV. Here, iaNP increased APCs in the target tissue, lymph node, along with the 
spleen while no change was seen in DCs or macrophages in the lung tissue (Figure 2.7). In the 
lymph node we saw a broad activation of dendritic cell subpopulations (Figure 2.7A). iaNP 
increased activated cDC1 population by 1.4 fold with no change in the NP only treatment (Figure 
2.7B). cDC2 and pDC counts were also significantly increased only in the iaNP treatment group 
compared to NP only and control (Figure 2.7C,D).  
While the spleen monocytes, macrophages, and B cell populations were unchanged with 
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iaNP treatment, a significant increase in DC populations including cDC1, cDC2 and pDC was 
seen (Figures 2.7E-K). The B cell population in the splenocytes was not significantly changed 
with the treatment (Figure 2.7G). While the iaNPs increased activated DC populations, there was 
no effect on the spleen or lung monocyte populations (Figure 2.7E,L). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: iaNP are preferentially internalized by antigen presenting cells ex vivo. (a-d) 
Quantification of Dendritic Cell (DC) populations in splenocytes (A) MHCII+CD11c+CD86+ 
dendritic cells (B) CD11c+CD8+CD11b-CD86+ conventional dendritic cells 1 (cDC1) (C) 
CD11c+CD8-CD11b+CD86+ conventional dendritic cells 2 (cDC2) (D) CD11c+CD8-CD11b-
B220+MHCII+CD86+ plasmacytoid dendritic cells (pDC) (E) Quantification of CD3-B220+CD86 
B cell population of all CD45+ cells in splenocytes.  (F,G) IL-10 and IL-12 expressing 
macrophages in splenocytes by intracellular cytokine staining. Each data point in the panels 
consist of one animal. One-way ANOVA, * denotes p<0.05, ** p<0.01, *** p<0.001. 
 
In the lung tissue which was distal to the site of activation of T cells, there was a local increase in 
macrophages with iaNP (Figure 2.7M). Additionally, in the lung there was no change in IL-10 
production from macrophages but a significant increase in IL-12 production was seen similar to 
the the ex vivo experiments (Figure 2.7N,O). These results demonstrate a mechanism by which 
iaNP delivered systemically induced APC activation in lymph nodes and tumor resident tissues. 
Furthermore, IL-12 secretory macrophages were induced in the tumor microenvironment, which 
may also be contributing to the observed anti-tumor efficacy of these iaNPs. 
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Figure 2.7: Systemically administered iaNP selectively induces DC activation in primary 
lymphoid tissues. (A-D) Lymph node antigen presenting cell CD86 expression in (A) CD8+ 
CD11b-CD86+ dendritic cells (B) CD8+CD11b-CD86+ conventional dendritic cells 1 (C) CD8-
CD11b+CD86+ conventional dendritic cells 2 (D) CD8-CD11b-B220+MHCII+CD86+ 
plasmacytoid dendritic cells. Activation of monocytes and macrophages in splenocytes (E) 
CD11b+CD64+Ly6c+ Monocytes (F) CD11b+CD64+Ly6c- CD64+ Macrophages (G) Spleen CD3-
B220+CD86+ B cells (H-K) Antigen presenting cell activation in splenocyte cell populations (H) 
MHCII+CD11c+CD86+ Dendritic cells (I) CD8+CD11b-CD86+ cDC1 cells (J) CD8-
CD11b+CD86+ cDC2 cells (K), CD8-CD11b-B220+MHCII+CD86+ pDC cells, (L, M) Activation 
of monocytes and macrophages in lung cell (L) CD11b+CD64+Ly6c+ Monocytes (M) 
CD11b+CD64+Ly6c- CD64+ Macrophages (N,O) IL-10 and IL-12 expressing macrophages in 
lung cells by intracellular cytokine staining. Data presented as mean ± s.d N=5. Each data point 
represents one animal. One-way ANOVA. * denotes p<0.05, ** p<0.01, *** p<0.001. 
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Immune response activated by iaNP 
 The	cytokine	levels	of	iaNP	treated	mice	was	analyzed	by	flow	cytometry.	Mice	were	injected	IV	with	B16F10	melanoma	on	day	0	and	treated	with	control,	NP	only,	or	iaNP	intravenously	over	10	days	then	sacrificed	at	day	14	(Figure	2.8A).	After	sacrifice	the	tissues	were	dissociated	to	single	cell	level	and	in	aggregate	activated	with	the	antigen	TRP-2.	Here	we	were	able	to	induce	the	production	of	cytokines	from	TRP-2	sensitive	cells	across	all	CD4	and	CD8	populations.	First,	we	analyzed	the	cell	and	cytokine	populations	in	the	target	lung	tissue	where	the	melanoma	foci	localize.	NP	only	and	iaNP	significantly	increased	IFNg	in	the	lung	population	for	effector	T	(Teff)	cells	compared	to	control	(Figure	2.8B).	The	iaNP	also	resulted	in	an	increase	in	the	production	of	IFNg	in	the	CD8	cells	in	the	lung	(Figure	2.8D).	TNFa	production	for	Teff	and	CD8	populations	in	the	lungs	was	not	changed	with	treatment	(Figure	2.8C,E).	We	further	investigated	the	effects	on	distal	tissue	populations	from	the	site	of	desired	T	cell	effects,	lymph	nodes	and	spleen.	iaNP	treatment	did	not	alter	the	Teff	cytokine	production	of	IFNg	and	TNFa	in	the	lymph	node	(Figure	2.8F,G).	Additionally,	we	observed	a	trending	increase	in	CD8+	IFNg	production	in	the	lymph	node	with	iaNP	treatment	but	no	change	in	TNFa	production	(Figure	2.8H,I).	In	the	spleen	tissue	interestingly,	iaNP	significantly	decreased	the	IFNg	and	TNFa	production	of	Teff	cells	with	NP	only	and	iaNP	treatment	(Figure	2.8J,K).	Similarly,	we	saw	a	decrease	in	the	TNFa	production	of	CD8	cells	in	the	spleen	while	no	difference	was	seen	with	the	IFNg	production	with	treatment	(Figure	2.8L,M).	Importantly,	the	iaNP	treatment	did	not	alter	the	T	regulatory	(Treg)	cell	populations	in	the	LN,	spleen,	and	lung	tissues	(Figure	2.8N-P).	Here	we	demonstrate	not	only	DC	activation,	but	evidence	of	the	induction	of	TRP-2	sensitized	T	cells	in	the	target	tumor	environment	of	the	lungs. 
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Figure 2.8: iaNP induces TRP-2 sensitized T cells in the tumor environment in the lungs. 
(A) Timeline (days) for B16F10 melanoma cell intravenous inoculation, treatments, and sacrifice 
for tissue harvest. Cells are stimulated in aggregate with TRP-2 in culture. (B,C) IFNg and TNFa 
expressing CD4+FOXP3- effector T cells in lung by intracellular cytokine staining. (D,E) IFNg 
and TNFa  expressing CD45+CD8+ cytotoxic T cells in lung (F,G) Teff and CD8 IFNg staining 
in lymph node cells. (H-J) Teff cells in splenocytes (H) CD4+FOXP3- effector T cells (I) IFNg 
(J) TNFa. (K-M) CD8 cells in splenocytes (K) CD45+CD8+ cytotoxic T cells (L), IFNg (M), 
TNFa. (N-P) CD4+FOXP3+ Treg cell population in (N) Lung (O) Spleen (P) Lymph Node. 
Each data point represents one animal. One-way ANOVA. * denotes p<0.05, ** p<0.01, *** 
p<0.001.   
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Discussion 
Immune agonists are promising potent cancer immunotherapies that can lead to decreased 
tumor size and metastasis. Combination therapies have shown promising results combining 
immune stimulators with tumor specific antigens.40,46–48 CpG ODNs mimic Toll-like receptor 
(TLR) ligands and are robust immune stimulators and inducers of IFN alpha production and DC 
maturation.16 RIG-I agonists have been shown to be a potent pathway to trigger the RIG-I 
pathway leading to an IFN-mediated antiviral response.49  STING agonists have been shown to 
induce production of IFN-b upon binding to STING, enhancing the activation of DCs.50 We 
hypothesize that the combination of these innate agonists, TLR9 agonist, RIG-I agonist, and 
STING agonist, to enhance dendritic cell activation and presentation with a tumor specific 
antigen to prime T cells to the tumor will lead to enhanced downstream T cell anti-tumor 
activity. However, the instability, short half-life, and potential systemic toxicity of these small 
molecules can lead to rapid clearance and decreased therapeutic benefit.37,44 Additionally, 
ongoing clinical trials with IT treatment of STING agonists (ClinicalTrials.gov number 
NCT03010176, NCT03172936) have been promising; however, IT injections are not always 
feasible based on the tumor type.   
Here, we showed coencapsulation of innate TLR9, RIG-1 and STING agonists with 
tumor specific antigen (gp-100 or TRP-2) in biodegradable PLGA nanoparticles led to a decrease 
in tumor volume compared to the unencapsulated ligand combination and PBS vehicle when 
administered IV in a subQ melanoma tumor model. Interestingly, nanoparticle treatment did not 
increase efficacy with IT treatment. We hypothesize that since when injected IT the drug 
compounds were localized in the tumor, a therapeutic effect resulted with and without the 
nanoparticles. However, with IV injection the unencapsulated drugs can be cleared quickly 
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resulting in decreased efficacy in reducing tumor volume compared to the iaNP formulation. 
While treatment with IT injection is possible for subQ melanoma tumors, other examples 
of cancers such as most solid tumors and blood cancers would not be feasible to perform IT 
injections. Since iaNP compared to unencapsulated drug combinations administered IV led to a 
significantly better efficacy, we believe the need to encapsulate the drug combination is essential 
for efficient delivery of these therapeutics. In a lung melanoma metastasis model, iaNP treatment 
decreased tumor burden in the lung tissue compared to control and NP only treatment. There was 
a modest decrease with NP only compared to control which suggests the nanoparticles alone 
generated a nonspecific immune response leading to a decrease in foci.51 However, when the 
nanoparticles were loaded with the immune agonist cocktail, we saw a significant decrease in 
foci indicating a more specific and potent response. 
Next, we wanted to understand the interactions between the nanoparticles and the DC and 
T cells that led to this therapeutic response. DC presentation and activation is necessary for the 
subsequent activation of T cells. To prime the immune system the nanoparticles first have to 
enter the desired APC population. We demonstrated in vitro that fluorescently labelled PLGA 
NPs were selectively internalized by cDC, pDC and macrophages with limited internalization 
into T and B cells. Once the nanoparticles enter the cells the innate agonists dissociate from the 
nanoparticle resulting in release of these therapeutics to the desired cell populations with 
expected downstream activation of these cells. 
Overall, in vivo we showed an increased activation across DCs with iaNP in lymph nodes 
and splenocytes. Since, the different populations of DC such as cDC1, cDC2, and pDC can lead 
to different therapeutic responses we further investigated these cell types in lymph node, spleen, 
and lung tissue of mice treated with iaNP. Lymph node tissue is a target tissue for DC activation 
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since it is the main site of interaction with T cells to activate and prime the T cells to the tumor 
cells. In vivo, iaNP treatment increased activated DCs in lymph node and spleen tissue. cDC1 
activation results in the cross presentation of antigen through MHCI to activate CD8 T cells to 
promote T helper type I and NK responses.52,53 We showed with iaNP treatment, the number of 
cDC1 activated cells increased in lymph node and spleen tissue. While we also showed an 
increase with cDC2 cells, these cells are activated by TLRs such as RIG-I and stimulate CD4+ T 
cells. cDC2 are associated with promotion of Th2 which activate B cells to produce 
antibodies.52,53 Here we showed that an activated B cell population moderately increased with 
iaNP treatment. Since B cells may produce tumor specific antibodies to opsonize tumor cells and 
trigger NK to kill them this would be an interesting finding to further investigate. pDCs migrate 
through the blood and lymphoid tissue which stimulates type I interferons resulting in the 
stimulation and activation of T cells.52,53 The activated pDC population increased with iaNP 
treatment in both lymph nodes and splenocytes.  
Since 30% of the macrophages internalize nanoparticles, we showed that with iaNP the 
macrophage population increased in the lung while no difference was seen in the splenocytes. 
Macrophages produce cytokines IL-10 and IL-12; IL-10 has been shown to limit the extent of 
activation of innate and adaptive immune cells while IL-12 is a proinflammatory cytokine that is 
produced by APCs and can further activate NK cells and induce differentiation of CD4 T cells to 
IFNg producing T helper 1 effectors.54 Here we showed that in the lungs there was no change in 
the IL-10 production and an increase in IL-12 production of macrophages with iaNP treatment in 
vivo. The monocytes did not show an increase in the spleen or lung tissues indicating the main 
effect with the iaNP was the activation of DCs in the lymph node and spleen along with 
macrophages in the lungs. 
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Along with co-encapsulation of the agonists to enhance DC activation and presentation, 
we encapsulated a peptide specific to melanoma cancer with the goal to sensitize T cells to this 
peptide allowing for the generation of T cells with this peptide specific receptor on the surface 
which can then target the specific protein on the melanoma cancer cells. For this analysis we 
utilized the TRP-2 peptide and the metastatic melanoma model. When cytotoxic T cells are 
activated, they can target and kill tumor cells with multiple strategies including secretion of 
cytokines such as IFNg and TNFa. After culturing the single cells from the tissue with TRP-2 we 
showed an increase in lung Teff and CD8 production in IFNg. The T cell activation was minimal 
in the lymph node compared to the lung which indicated that the T cells have migrated from the 
lymph node to the site of action where the melanoma was present in the lungs. Interestingly, we 
also showed a decrease in the Teff IFNg producing cells indicating these cells have migrated 
away from the spleen and to the site of action where we saw an increase in IFNg producing cells. 
In summary, we demonstrated nanoparticle loading with an adjuvant agonist cocktail to 
reduce mouse tumor burden in a subQ and metastatic melanoma mouse model. Nanoparticles 
were efficiently internalized by APC resulting in activation of these cell populations. APC 
activation led to an increase in activated T cells primed against the melanoma target to result in 
an increase in cytokine production and decrease in melanoma. Further investigation of these 
systemically infused innate activating particles combined with other adaptive immunity 
therapeutic approaches such as PD-1 combinations is supported by the current studies. 
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CHAPTER 3:  Tissue-Factor Targeted Benzo-Resolvin and Resolvin D1 Loaded 
Nanoparticles to Locally Deliver Anti-Inflammatory Compounds Following Vascular 
Intervention  
 
Abstract 
Inflammation and plaque rupturing due to atherosclerosis can lead to clot formation and 
thrombosis. Current strategies to mediate coronary artery disease include balloon angioplasty and 
stents. However, these techniques have limitations with limited long-term success and 
occurrence of restenosis. Pro-resolving lipid mediators (SPMs) are naturally produced at 
inflammation sites and have been shown to play an important role in the anti-inflammatory 
response. Resolvin D1 (RvD1) and benzo-diacetylenic-17R-RvD1-methyl ester (BDA-RvD1) 
are part of the SPM family of compounds that have been shown to attenuate inflammation and 
improve recovery after tissue injury. In this study, we present a biodegradable tissue factor 
targeting poly (lactic-co-glycolic acid) (PLGA) polymer-based nanoparticles (NP) loaded with 
RvD1 or BDA-RvD1. We validated the loading and release of RvD1 and BDA-RvD1 from the 
NPs. RvD1 NPs were biocompatible and attenuated vascular smooth muscle cell (VSMC) 
migration. Tissue factor targeted NPs increased localization and RvD1 amounts to damaged 
artery regions where the epithelial cell layer was disrupted, and tissue factor was exposed. BDA-
RvD1 NP increase tissue concentrations compared to BDA-RvD1 gel. Our results demonstrate a 
materials-based approach to achieve increased local concentrations of anti-inflammatory drug 
loaded NP to target damaged regions in the arterial wall. 
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Introduction  
Cardiovascular disease is one of the leading causes of death in the world.1 Atherosclerotic 
disease chronic inflammation of the artery walls resulting in plaque formation. Rupturing of the 
plaque in the arteries exposes tissue factor, leading to coagulation cascades and clot formation 
resulting in thrombosis and acute coronary syndromes.2 Patients with chronic inflammatory 
disease such as cystic fibrosis and asthma have decreased levels of pro-resolving lipid mediators 
(SPMs).3,4 These SPMs are produced naturally in the body as a key regulator of the anti-
inflammatory response.5 
SPMs derived from w-3-poly-unsaturated fatty acids are enzymatically oxygenated lipid 
mediators that function to reduce inflammatory response. 6 Resolvin D1 (RvD1) and benzo-
diacetylenic-17R-RvD1-methyl ester (BDA-RvD1) are part of the class of SPMs which have 
been shown to play an active role in reduction of inflammation in a variety of diseases such as 
colitis, periodontitis, and lung injury.7 SPMs have been shown to regulate not only the innate 
phagocyte response for acute inflammation but also regulates adaptive responses through 
cytokine regulation of innate lymphoid, natural killer, T, and B cells which have a SPM 
receptor.8 RvD1 is derived from docosahexaenoic acid (DHA) that is formed in inflammatory 
exudates. RvD1 has been shown to halt neutrophil migration and protect against 
polymorphonuclear neutrophil granulocyte-mediated ischemia-reperfusion injury.8,9 However, 
delivery of RvD1 has been challenging due to the instability of the compound. An analog, BDA-
RvD1 has been developed to increase chemical stability and reduce metabolism which is a major 
pathway that reduces the activity of RvD1.10 Even though the BDA-RvD1 derivation increases 
stability, the systemic half-life of these small molecules is limited. 
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Alternatives to small molecules like SPMs include many other interventions for coronary 
artery disease such as coronary balloon angioplasty, stents and wraps.11 However, these 
techniques are invasive and can lead to restenosis which occurs in 30 to 50% of the patients with 
angioplasty, limiting therapeutic benefits.12–14 Stents have shown promise over balloon 
angioplasty with improved luminal diameters, but long term treatment has limited success.14–16  
Nanoparticles (NPs) have developed as a powerful tool to target and deliver therapeutics to 
desired regions of the body.17,18 NPs have been shown to allow for protection of small molecules 
to increase systemic half-life and reduce degradation.19,20 Strategies have also been developed to 
target the NPs to desired areas of the body. Targeting NPs allows for a local increase of a 
therapeutic to the desired region while limiting off target toxic side effects.21 To target damaged 
regions of arteries, a peptide was developed to bind to tissue factor (TF).22 Since the epithelial 
layer is disrupted in damaged regions,  this leads to exposure of the basement membrane protein, 
TF.  
Materials and Methods 
Peptide polymer conjugation 
The TF targeting peptide sequence was {Lys(FITC)}CGGGKFRVFALTR while a 
randomized sequence of the same amino acids was used for the nonsense or nontargeting peptide 
sequence control {Lys(FITC)}CGGGARVFTFRLK.22 The TF targeting peptide and nonsense 
peptide were first conjugated to PLGA-PEG-maleimide 10k-5k (PolySci Tech). Two different 
molar ratios were tested (2:1 and 5:1 of peptide to PLGA-PEG-maleimide polymer ratio) where 
the peptide was added to the PLGA-PEG-maleimide (30 mg/mL) in DMF with 6% v/v Et3N. The 
mixture was reacted overnight to conjugate the thiol of the cysteine on the peptide to the PLGA-
PEG-maleimide. The DMF was evaporated by high spin vacuum. Samples were stored at -20°C.  
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Nanoparticle fabrication 
 PLGA NPs with a diameter of 250 nm were fabricated as previously described.23 Briefly, 
a solution consisting of 100 mg of 100/0, 85/15, 75/25 or 50/50 lactic acid/glycolic acid (L/G) 
ratio of poly(lactic-co-glycolic acid (PLGA) in dichloromethane (DCM) (50 mg/mL) and 
poly(2,5-di(hexyloxy)cyanoterephthalylidene (CN-PPV) (3.25 mg/mL) in chloroform (Sigma) 
was combined. RvD1 (200 ng) or Benzo-RvD1 (2000 ng) were added to NPs in ethanol. For NPs 
with the peptide on the surface, either targeting or nonsense peptide conjugated to PLGA-PEG-
maleimide (20 nmol) was added to 50 mg of PLGA and 3% (w/v) polyvinyl alcohol (PVA) was 
added at a 1:2 ratio of polymer solution to 3% PVA (v/v). The solution was probe sonicated on 
ice at 7-8 W or 30 amplitude for 5 seconds on and 10 seconds off for a total of 5 cycles to form 
stable NPs. The NP solution was diluted 10X with 0.3% (w/v) PVA and stirred for 2 hours to 
evaporate the DCM. NPs were then purified by a soft wash at 500 rpm to remove large 
aggregates, then washed 3X with 1% (w/v) PVA to remove small NPs and unencapsulated drug 
by centrifugation at 12,500 rpm for 10 minutes. The NPs were then lyophilized and stored at -
80°C. Prior to studies, the NPs were resuspended in Phosphate Buffered Saline (PBS) or 10% 
FBS DMEM media.  
Release studies 
Nanoparticle release was evaluated in vitro with PBS as an elution buffer. NPs were 
incubated with 400 µL of PBS in Eppendorf tubes while shaking at 37°C. At different time 
points, tubes were scarified and the amount of RvD1 or BDA-RvD1 in the supernatant was 
measured. Time points measured were 30 minutes, 3 hours, 1 day, 3 days, and 5 days. Samples 
with RvD1 were analyzed with a 17S-Resolvin D1 enzyme immunoassay kit (Cayman 
Chemical) and samples with BDA-RvD1 were analyzed by LC-MS/MS.11 The functional, in 
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vitro and in vivo experiments, were performed with 17R-RvD1 which is therapeutically relevant 
while the release and loading was determined with 17S-RvD1 since the ELISA was specific and 
more sensitive to 17S-RvD1. 
Total drug payload 
Maximum loading of RvD1 or BDA-RvD1 in the NPs was measured by dissolving the 
NPs in 1M NaOH until the solution turned clear. The solution was neutralized with HCL and 
diluted with 10X PBS. The samples were then run on ELISA for RvD1 and LC-MS/MS for 
BDA-RvD1. 
Cell culture 
Viability 
Human greater saphenous vein discarded during operations at the University of 
California San Francisco was used to prepare primary cell cultures of vascular smooth muscle 
cells (VSMCs), as previously described.24 Cells between passage numbers 3-5 were used for all 
experiments. For viability experiments, cells were seeded at 1x104 cells and incubated with NP 
loaded with RvD1 and RvD1 only at different concentrations, along with a no treatment group. 
Treatment continued for 24 hours prior to performing the PrestoBlue viability assay. The media 
or buffer was removed and PrestoBlue cell viability Reagent (Invitrogen) was added to the wells 
for 10-minutes at 37°C. The absorbance was read at 570 nm. Wells without NPs or RvD1 were 
used as controls.  
Migration assay 
VSMCs were seeded and grown to confluency on 24-well plates with 10% FBS DMEM 
and serum starved overnight. A scratch was made in the well with a sterile pipette tip and 
imaged. An agonist containing platelet-derived growth factor homodimer BB (PDGF-BB) (10 
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ng/mL) was added to all the wells to increase migration. The wells were imaged again after 12 
hours. The migration was compared at 0 hours and 12 hours and distance was calculated using 
Image J software.  
Tissue factor targeting in vitro 
Peptide loading was determined by quantifying the amount of peptide incorporated in the 
NPs by using the fluorescein isothiocyanate (FITC) tag on the peptide. The FITC fluorescence 
was measured on the NPs by using a plate reader at ex/em 490/525 nm.  
For tissue factor plate binding assays a 96 well plate was incubated with different concentrations 
of tissue factor to coat the plate. NPs with TF target peptide or nonsense peptide were incubated 
in the tissue factor coated wells. The NPs were washed to remove unbound NPs and the 
fluorescence was quantified on a plate reader at ex/em 490/525 nm. 
Tissue factor targeting In vivo 
Balloon angioplasty was performed on the coronary artery for 10 minutes to create 
damaged regions of the artery as a model. A no injury control was performed for comparison. 
Arteries were then incubated with TF target NP or nonsense peptide NP. The artery sections 
were visualized by microscopy to determine the location of the NPs. Target peptide NP and 
nonsense peptide NP loaded with RvD1 were incubated in the artery after balloon angioplasty for 
10 minutes. After 10 minutes, blood flow was restored. Acute sacrifice was performed after 10 
minutes and the amount of RvD1 in the tissue was determined by LC MS/MS. Benzo-RvD1 was 
quantified in the tissue 10 minutes and 3 days after blood flow was restored by LC MS/MS. 
Treatment groups include BDA-RvD1 loaded NPs and BDA-RvD1 in a gel.  
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Statistics 
Statistical analysis was performed by a one-way ANOVA with a Dunnett multiple 
comparison correction to determine significance between groups. Graphs show the mean ± 
standard deviation (SD) where * represents p<0.05, ** represents p<0.01, and *** represents 
p<0.001. 
 
Results 
Nanoparticle characterization 
 NPs were fabricated by single emulsion probe sonication. Briefly, the polymer and RvD1 
or BDA-RvD1 were dissolved in the organic phase. The organic phase was probe sonicated with 
the aqueous 3% PVA surfactant phase to make stable NPs. NPs were visualized with SEM and 
DLS with an average size of 259.6 ± 18.1 and pdi of 0.099 (Figure 3.1A, B).  
 The loading and release of RvD1 NPs was determined for different L/G ratios of PLGA 
by ELISA. PLGA with 75/25 of L/G ratio performed optimally with the highest amount of RvD1 
loading resulting in an increased amount of RvD1 release over time (Figure 3.1C, D). The 
loading of RvD1 in the NPs was 0.5 ng of RvD1/mg NP with an encapsulation efficiency of 
25%. BDA-RvD1 was encapsulated in 75/25 L/G PLGA at 0.37 ng BDA-RvD1/mg NP. Altering 
the L/G ratio of PLGA affects the loading and release due to polymer hydrophobicity and to the 
increased polymer degradation with higher amounts of glycolic acid.25–27 Interestingly, 75/25 had 
the highest loading. As a result, with further experiments we chose to use the 75/25 L/G ratio 
PLGA polymer.  
 
	 66	
200 nm
0
200
400
600
pg
 R
vD
1/
m
g 
N
P
RvD1 Nanoparticle Loading
***
100/0 L:G
85/15 L:G
75/25 L:G
50/50 L:G
0 50 100 150
0
50
100
150
200
RvD1 Nanoparticle Release Study
Time (hours)
pg
 R
vD
1/
m
g 
N
P 100/0 L:G85/15 L:G
75/25 L:G
50/50 L:G
***
A) B)
C) D)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: NP characterization. (A) Schematic representation of RvD1 loaded NP with CN-
PPV polymer and surface peptide. (B) Scanning electron microscope image of NPs with 200 nm 
scale bar. Varying 100/0, 85/15, 75/25, 50/50 L/G ratio of PLGA to optimize (C) RvD1 NP 
loading (one-way ANOVA, Mean ± SD; n=3, *** p<0.001) (D) RvD1 NP release studies (two-
way ANOVA, Mean ± SD; n=3, *** p<0.001). 
 
Human vascular smooth muscle cell in vitro migration assay 
 RvD1 functions as an anti-inflammatory agent that is utilized during arterial injury.8 
Smooth muscle cells migrate in response to damaged arteries which can lead to intimal 
hyperplasia.28 One function of RvD1 is to reduce migration of smooth muscle cells.29 First, we 
confirmed that the cell viability of the VSMC was not altered by the NPs (Figure 3.2A). VSMC 
were cultured in a 24 well plate and a scratch assay was performed to study the migration 
response of these cells with treatment. RvD1 NP at 8.3 mg/mL, which based on the loading is 
equivalent to 10 nM RvD1, decreased migration compared to unloaded NP and similarly to 
treatment with 10 nM RvD1 (Figure 3.2B). As smooth muscle cells can accumulate at the site of 
an injury, this can lead to intimal hyperplasia. The ability of the RvD1 to release from the NPs 
and modulate the migration of VSMC is important. 
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Figure 3.2: Characterization of nanoparticles in VSMC. 8.3 mg/mL RvD1 NP based on 
loading is equivalent to a dose of 10 nM and 83.3 mg/mL RvD1 NP based on loading is 
equivalent to a 100 nM dose. (A) Biocompatibility studies of the NPs on VSMC for 24 hours 
with PrestoBlue assay (one-way ANOVA, Mean ± SD; n=3). (B) VSMC migration assay with 
RvD1 only, NP only, and RvD1 NP compared to a growth factor agonist (one-way ANOVA, 
Mean ± SD; n=3, ** p<0.01). 
 
Peptide targeting nanoparticles to tissue factor 
 Bypass graft failures can lead to atherosclerosis which results in damaged regions of the 
artery where the epithelial layer is not intact.30 This leads to arterial exposure to TF. We aim to 
target this TF to localize the NPs to the damaged regions for local delivery of RvD1 and BDA-
RvD1 to these desired areas. Through thiol maleimide conjugation, the peptide with a cysteine 
handle was attached to PLGA-PEG-maleimide. This was then added to PLGA, CN-PPV, and 
RvD1 or Benzo RvD1 prior to probe sonication to form the NPs. The peptide was tagged with 
FITC to quantify the amount incorporated into the NPs. With increasing ratio of peptide to 
PLGA-PEG-maleimide, the amount of peptide on the NP increases (Figure 3.3A). The nonsense 
peptide incorporates similarly to the targeted peptide in the NPs (Figure 3.3A). To understand the 
specificity of the targeted peptide to TF, an in vitro TF plate binding assay was performed. The 
two higher doses of RvD1 loaded NP lead to a significant difference between the TF targeted NP 
and the nonsense NP (Figure 3.3B). TF targeted NP binding was significantly enhanced 
compared to nonsense NP with 500 ng and 250 ng of TF coated on the wells (Figure 3.3C). 
In vivo targeting was performed by creating a damaged region on the rat artery by 
angioplasty then incubation of NP with either TF targeting peptide or nonsense peptide. CN-PPV 
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is a fluorescent polymer that was incorporated in the NP to allow for tracking of the NP in the 
artery. The damaged region from the angioplasty was visible in the artery where the epithelium 
was disrupted. TF targeted peptide NP was more localized to the damaged portion of the artery 
compared to the nonsense peptide NP which was minimally retained (Figure 3.3D). The goal is 
to localize the therapeutic RvD1 or BDA-RvD1 to damaged artery regions to reduce the 
inflammation and prevent intimal hyperplasia that could lead to atherosclerosis. In addition, 
localization to desired regions allows for an increased local dose to improve therapeutic efficacy. 
The TF targeted peptide compared to a nonsense peptide selectively colocalized with the 
damaged regions of the artery.  
In vivo RvD1 and BDA-RvD1  
An in vivo injury model represents a more physiological environment to test the NP 
targeting and RvD1 and BDA-RvD1 delivery to injured tissue. Balloon angioplasty was 
performed for 10 minutes to create a damaged region of the artery. NPs with the TF target 
peptide and NPs with the nonsense peptide conjugated to the surface were administered to the 
damaged region, incubated for 10 minutes then blood flow was restored. Not only were the NPs 
with the TF targeting peptide highly localized to the artery compared to the nonsense peptide 
NPs (Figure 3.3D), but there was also more RvD1 present in the TF targeted NPs after acute (10 
minutes) sacrifice (Figure 3.4A). BDA-RvD1 NPs were detectable after 10-minute incubation 
and still after 3 days. When normalizing the BDA-RvD1 by the starting dose there was 
significantly more BDA-RvD1 present in the NP group compared to the BDA-RvD1 gel group 
(Figure 3.4B). The gel formulation has been used in animal models to deliver perivascular drug 
molecules.31 
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Figure 3.3: NP with TF targeting peptide increases association with TF and damaged 
artery regions. (A) Peptide loading characterization with a peptide/polymer (P/P) ratio of 2 and 
5 for the target peptide and a ratio of 5 for the nonsense peptide/polymer ratio. + control well has 
no detectable fluorescence signal (one-way ANOVA, Mean ± SD; n=3, **p<0.01). TF coated 
plate with TF targeted NP and nonsense NP altering (B) NP concentration or (C) TF amount per 
well (one-way ANOVA, Mean ± SD; n=3, **p<0.01). (D) In vivo artery with damaged regions 
by angioplasty compared to no injury between TF targeted NP and non-targeted or nonsense NP. 
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Figure 3.4: In vivo drug quantification by LC MS/MS. (A) Upon administering the nonsense 
and targeted RvD1 loaded NP, the tissue was sacrificed 10 minutes later and the RvD1 
concentrations were measured (one-way ANOVA, Mean ± SD). (B) Amounts of BDA in tissue 
when BDA-RvD1 was administered by gel and NP after 3 days (one-way ANOVA, Mean ± SD, 
**** p<0.0001, n =3).  
 
Conclusions 
 The importance of targeting and local concentration of a therapeutic molecule to 
damaged regions of the artery is well recognized in the cardiovascular field. Current clinical 
techniques focus on coronary balloon angioplasty and stents. However, these are invasive and 
can be difficult to administer. There is a critical need for development of strategies to locally 
release therapeutics in targeted damaged regions. Here, a materials-based approach was applied 
to study the effects of tissue factor targeted nanoparticles loaded with either RvD1 or BDA-
RvD1 along with CN-PPV, a fluorescent polymer for visualization, on damaged regions of 
arteries. We demonstrated the NPs can be loaded with either RvD1 or BDA-RvD1 in a single 
emulsion to form stable NPs. With the addition of CN-PPV the NPs could be visualized by 
microscopy to study the localization and distribution of the NPs after treatment. A peptide that 
targets TF was conjugated to the surface of the NPs, allowing for local delivery to damaged 
arteries where TF was exposed, with the goal to maximize drug release in desired areas while 
limiting off target toxic effects. After an injury to the artery, more RvD1 was present in the 
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tissues when dosed in a NP formulation with a TF targeting peptide compared to a nonsense 
peptide. Additionally, in the presence of the NP the BDA-RvD1 amount in the tissue was 
significantly greater than the gel formulation. We believe this approach can be utilized to target 
particular regions of the artery to locally delivery a stable therapeutic compound. Future work 
will continue to characterize the effects of the NPs and optimize the response in the injury 
model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 72	
References 
1. Mc Namara, K., Alzubaidi, H. & Jackson, J. K. Cardiovascular disease as a leading cause of 
death: how are pharmacists getting involved?. Integr. Pharm. Res. Pract. 8, 1–11 (2019). 
2. Badimon, L., Padró, T. & Vilahur, G. Atherosclerosis, platelets and thrombosis in acute 
ischaemic heart disease. Eur. Hear. J. Acute Cardiovasc. Care 1, 60–74 (2012). 
3. Duvall, M. G., Krishnamoorthy, N. & Levy, B. D. Non-type 2 inflammation in severe asthma 
is propelled by neutrophil cytoplasts and maintained by defective resolution. Allergol. Int. 
68, 143–149 (2019). 
4. Eickmeier, O. et al. Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung 
disease in cystic fibrosis. PLoS One 12, 1–12 (2017). 
5. Wang, R. X. & Colgan, S. P. Special pro-resolving mediator (SPM) actions in regulating 
gastro-intestinal inflammation and gut mucosal immune responses. Mol. Aspects Med. 58, 
93–101 (2017). 
6. Bannenberg, Gerard, Serhan, C. N. Specialized Pro-Resolving Lipid Mediators in the 
Inflammatory Response: An Update. Biochim Biophys Acta. 1801, 1260–1273 (2010). 
7. Gu, Z. et al. Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory 
axis in TLR4-engaged human monocytes. Innate Immun. 22, 186–195 (2016). 
8. Serhan, C. N. & Levy, B. D. Resolvins in inflammation: emergence of the pro-resolving 
superfamily of mediators Protection versus uncontrolled inflammation: first responders 
and resolution. J Clin Invest 128, 2657–2669 (2018). 
9. Kasuga, Kie, Yang, Rong, Porter, Timothy F., Agrawal, Nitin, Petasis, Nicos A., Irimia, 
Daniel, Toner, Mehmet, Serhan, C. N. Rapid Appearance of Resolvin Precursors in 
	 73	
Inflammatory Exudates: Novel Mechanisms in Resolution. J Immunol. 181, 8677–8687 
(2008). 
10. Orr, S. K., Colas, R. A., Dalli, J., Chiang, N. & Serhan, C. N. Proresolving actions of a new 
resolvin D1 analog mimetic qualifies as an immunoresolvent. Am. J. Physiol. - Lung Cell. 
Mol. Physiol. 308, L904–L911 (2015). 
11. Lance, K. D. et al. Unidirectional and sustained delivery of the proresolving lipid mediator 
resolvin D1 from a biodegradable thin film device. J. Biomed. Mater. Res. - Part A 105, 
31–41 (2017). 
12. Kales, A. & Kales, J. D. Long-term follow-up after percutaneous translumincal coronary 
angioplasty. N. Engl. J. Med. 316, 1127–1132 (1987). 
13. Holmes, D. R. et al. Restenosis after percutaneous transluminal coronary angioplasty 
(PTCA): A report from the PTCA registry of the national heart, lung, and blood institute. 
Am. J. Cardiol. 53, 77–81 (1984). 
14. Grech, E. D. ABC of interventional cardiology: Percutaneous coronary intervention. I: 
History and development. Br. Med. J. 326, 1080–1082 (2003). 
15. Feldman, M. & Cryer, B. A randomized comparison of coronary-stent placement and balloon 
angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331, 496–501 
(1994). 
16. Bakken, A. M. et al. Long-term outcomes of primary angioplasty and primary stenting of 
central venous stenosis in hemodialysis patients. J. Vasc. Surg. 45, 776–783 (2007). 
17. Friedman, A., Claypool, S. & Liu, R. The Smart Targeting of Nanoparticles. Curr. Pharm. 
Des. 19, 6315–6329 (2013). 
	 74	
18. Jiang, T., Jin, K., Liu, X. & Pang, Z. Nanoparticles for tumor targeting. Biopolymer-Based 
Composites: Drug Delivery and Biomedical Applications (Elsevier Ltd, 2017).  
19. Kadam, R. S., Bourne, D. W. A. & Kompella, U. B. Nano-advantage in enhanced drug 
delivery with biodegradable nanoparticles: Contribution of reduced clearance. Drug 
Metab. Dispos. 40, 1380–1388 (2012). 
20. Hanson, M. C. et al. Nanoparticulate STING agonists are potent lymph node-targeted 
vaccine adjuvants. J. Clin. Invest. 125, 2532–2546 (2015). 
21. Dadwal, A., Baldi, A. & Kumar Narang, R. Nanoparticles as carriers for drug delivery in 
cancer. Artif. Cells, Nanomedicine Biotechnol. 46, 295–305 (2018). 
22. Morgan, C. E. et al. Tissue-factor targeted peptide amphiphile nanofibers as an injectable 
therapy to control hemorrhage. ACS Nano 10, 899–909 (2016). 
23. McCall, R. L. & Sirianni, R. W. PLGA nanoparticles formed by single- or double-emulsion 
with vitamin E-TPGS. J. Vis. Exp. 51015 (2013). doi:10.3791/51015 
24. Chatterjee, A. et al. The pro-resolving lipid mediator maresin 1 (MaR1) attenuates 
inflammatory signaling pathways in vascular smooth muscle and endothelial cells. PLoS 
One 9, (2014). 
25. Lü, J. M. et al. Current advances in research and clinical applications of PLGA-based 
nanotechnology. Expert Rev. Mol. Diagn. 9, 325–341 (2009). 
26. Swider, E. et al. Customizing poly(lactic-co-glycolic acid) particles for biomedical 
applications. Acta Biomater. 73, 38–51 (2018). 
27. Amann, L. C., Gandal, M. J., Lin, R., Liang, Y. & Siegel, S. J. In vitro-in vivo correlations of 
scalable plga-risperidone implants for the treatment of schizophrenia. Pharm. Res. 27, 
1730–1737 (2010). 
	 75	
28. Wadey, K., Lopes, J., Bendeck, M. & George, S. Role of smooth muscle cells in coronary 
artery bypass grafting failure. Cardiovasc. Res. 114, 601–610 (2018). 
29. Miyahara, T. et al. D-series resolvin attenuates vascular smooth muscle cell activation and 
neointimal hyperplasia following vascular injury. FASEB J. 27, 2220–2232 (2013). 
30. Parang, P. & Arora, R. Coronary vein graft disease: Pathogenesis and prevention. Can. J. 
Cardiol. 25, 57–62 (2009). 
31. Wu, B. et al. Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rabbit 
vein graft model Bian. J Vasc Durg. 68, 188S–200S (2018). 
 
 
 
 
 
 
 
 
 
 
 
 
	 76	
CHAPTER 4:  Conclusions 
 The work described here designs and implements various drug delivery strategies based 
on therapeutic characteristics and disease target to improve efficacy. Specifically, the focus was 
on designing nano- and micro- based delivery systems and utilizing them to increase drug 
delivery for oral drug administration, cancer immunotherapy, and atherosclerosis.  Numerous 
current drug formulations are small molecules, but these are typically cleared rapidly. Nano- and 
micro- carriers have been utilized to increase a drug’s systemic half-life, reduce degradation and 
allow for modulation such as adding targeting proteins to the surface.  
 Here we show for oral drug delivery, hydrogel based microdevices reversibly inhibited 
the intestinal efflux transporters, P-glycoprotein and Breast Cancer Resistance Protein. The drug 
delivery system was designed with hydrogel material since PEG hydrogels are non-
immunogenetic and biocompatible. To prevent the intracellular uptake of the hydrogels while 
still being able to have the material interact throughout the villus, the delivery system was 
designed to be micrometer size in diameter. This work builds a foundation for further 
investigation with this system such as optimizing loading of therapeutics in the microdevices to 
allow for local release of therapeutics only where the transporters are inhibited, to maximize 
drug absorption along with further investigating the effects of microdevice size on intestinal 
retention time.  
 For cancer immunotherapy, polymer nanoparticles loaded with an adjuvant cocktail 
including a RIG-I agonist, STING agonist, and TLR9 agonist along with a tumor specific peptide 
increased APC activation and decreased melanoma tumor size in a subQ model and lung foci 
number in a metastasis model. This system was designed to activate the immune system with a 
nanometer size for selective uptake into APCs and loading of therapeutics that once released 
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would promote not only APC activation but also presentation of the loaded peptide specific to 
melanoma. Additionally, the polymer was utilized due to its unique characteristic to biodegrade 
and clear naturally. The iaNPs not only promote APC activation but lead to downstream 
activation of melanoma sensitive T cells to result in reduction of tumor size and foci. This work 
builds a base for the benefits of combination and activation of multiple pathways to promote and 
increase the tumor response. Further optimization could be performed to determine the optimal 
dose and time frame to maximize the nanoparticle response to the tumor cells. 
 Lastly, in a system designed to reduce inflammation and damage from atherosclerosis, 
polymer nanoparticles were able to target damaged artery regions to locally release an anti-
inflammatory therapeutic. Successful conjugation of a tissue factor targeting peptide to the 
surface of the RvD1 and BDA-RvD1 loaded nanoparticles resulted in targeting to damaged 
regions of the artery where in these regions tissue factor is exposed.  
 Overall, these studies have developed the foundation for future ability to design drug 
delivery systems to promote local and targeted therapeutic release to desired regions to limit off 
target toxic effects. The advantage of the drug carrier systems can apply to many applications 
based on the desired outcome. Further utilization in industry applications has been limited, partly 
due to the ability to scale up these systems, but as technology such as the NanoAssemblr Blaze 
develops to scale up liposomes nanoparticles, I believe these drug delivery systems will be 
implemented more.  
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